Inventors list

Assignees list

Classification tree browser

Top 100 Inventors

Top 100 Assignees


Transgenic nonhuman animal (e.g., mollusks, etc.)

Subclass of:

800 - Multicellular living organisms and unmodified parts thereof and related processes

800008000 - NONHUMAN ANIMAL

Patent class list (only not empty are listed)

Deeper subclasses:

Class / Patent application numberDescriptionNumber of patent applications / Date published
800014000 Mammal 294
800020000 Fish 25
800019000 Bird (e.g., chicken, etc.) 16
Entries
DocumentTitleDate
20110179507LAGLIDADG HOMING ENDONUCLEASE VARIANTS HAVING MUTATIONS IN TWO FUNCTIONAL SUBDOMAINS AND USE THEREOF - A LAGLIDADG homing endonuclease variant, having mutations in two separate subdomains, each binding a distinct part of a modified DNA target half-site, said LAGLIDADG homing endonuclease variant being able to cleave a chimeric DNA target sequence comprising the nucleotides bound by each subdomain. Use of said herodimeric meganuclease and derived products for genetic engineering, genome therapy and antiviral therapy.07-21-2011
20110179506NEW I-CREI DERIVED SINGLE-CHAIN MEGANUCLEASE AND USES THEREOF - A new I-CreI derived single-chain meganuclease comprising two domains, each domain comprising a portion of a parent I-CreI monomer which extends at least from the beginning of the first alpha helix to the end of the C-terminal loop and said two domains being joined by a peptidic linker which allows them to fold as a I-CreI dimer that is able to bind and cleave a chimeric DNA target comprising one different half of each parent homodimeric I-CreI meganuclease target sequence. Use of said I-CreI derived single-chain meganuclease for genetic engineering, genome therapy and antiviral therapy.07-21-2011
20120174243SOGA Polynucleotides and Polypeptides and Uses Thereof - The present invention relates to the identification of polynucleotides and polypeptides involved in insulin and adiponectin signaling and regulation of glucose production. The invention further relates to the use of the identified polynucleotides and polypeptides, and inhibitors of the polynucleotides and polypeptides, in the regulation of glucose production and the monitoring and treatment of metabolic disorders such as diabetes.07-05-2012
20120174242OPLOPHORUS-DERIVED LUCIFERASES, NOVEL COELENTERAZINE SUBSTRATES, AND METHODS OF USE - An isolated polynucleotide encoding a modified luciferase polypeptide and substrates. The OgLuc variant polypeptide has at least 60% amino acid sequence identity to SEQ ID NO: 1 and at least one amino acid substitution at a position corresponding to an amino acid in SEQ ID NO: 1. The OgLuc variant polypeptide has at least one of enhanced luminescence, enhanced signal stability, and enhanced protein stability relative to the corresponding polypeptide of the wild-type 07-05-2012
20100088777Methods For Increasing The Resistance In Plants To Biotropic Fungi - The present invention relates to methods of generating or increasing resistance to at least one biotrophic pathogen in a plant or a part of a plant by increasing the protein quantity or function of at least one Bax Inhibitor-1 (BI-1) protein in at least one part of the plant. Moreover, the invention relates to polypeptide sequences and nucleic acid sequences which code for a BI-1 protein, and to expression cassettes, vectors and organisms which comprise such sequences or such a protein.04-08-2010
20110191870I-CREI HOMING ENDONUCLEASE VARIANTS HAVING NOVEL CLEAVAGE SPECIFICITY AND USE THEROF - A method for engineering I-CreI homing endonuclease variants able to cleave mutant I-CreI sites having variation in positions ±8 to ±10. A I-CreI homing endonuclease variant obtainable by said method, a vector encoding said variant, a cell, an animal or a plant modified by said vector. Use of said I-CreI endonuclease variant and derived products for genetic engineering, genome therapy and antiviral therapy.08-04-2011
20110197293SENSE AND ANTISENSE TRANSCRIPTS OF TRPM2 AND USES THEREOF - The present invention relates to a nucleic acid molecule being able to modulate the expression of the transient receptor potential cation channel, subfamily M, member 2 (TRPM2) gene and to modulate apoptosis and uses thereof.08-11-2011
20130031647HUMANIZED ANTI CXCR4 ANTIBODIES FOR THE TREATMENT OF CANCER - The present invention relates to a novel isolated humanized antibody, or the derived compounds or functional fragments of same, capable of binding to CXCR4 but also of inducing conformational changed of the CXCR4 homodimers and/or heterodimers. More particularly, the present invention relates to hz515H7 antibodies, specific to the CXCR4 protein, as well as their use for the treatment of cancer. Pharmaceutical compositions composed of such antibodies and a process for the selection of such antibodies are also covered.01-31-2013
20090300780Method for the humanization of antibodies and humanized antibodies thereby obtained - Method for the humanization of the VH and VL variable regions of an animal antibody of known sequence, humanized animal antibody obtainable according to the method, in particular anti-NGF and anti-TrkA humanized animal antibodies.12-03-2009
20090328243Secreted proteins as markers for cell differentiation - Provided are means and methods for in vitro and in vivo detection of chemically induced effects on embryonic development and differentiation for the purpose of embryotoxicity/teratogenicity screening as well as for the identification of pharmaceuticals such as growth and tissue promoting factors based on differentiating pluripotent embryonic stem (ES) cells. The assays are based on the use of transgenic ES cells and non-human animals comprising such ES cells or derivatives thereof, wherein said ES cells are characterized by the differentiation-dependent expression of a secreted reporter protein; in particular secreted embryonic alkaline phosphatase (SEAP).12-31-2009
20090320149Expression vectors - This present invention provides an expression vector system that uses alternative RNA processing to express in a single cell a polypeptide in both membrane-bound and soluble forms. By incorporating a mimetic structure of the 3′ terminal region of human mu gene and introducing other exogenous genetic elements, an artificial gene can be constructed that is capable of simultaneously expressing membrane-bound and secreted forms of polypeptides in myeloma cells and other cells of the B lymphocyte lineage, as well as in non-B cells. If an immunoglobulin heavy chain is co-expressed with a light chain using this vector, whole antibodies can be produced that are both displayed on the surface of a single cell and secreted into the cell culture supernatant. Membrane-bound antibodies facilitate isolation and expansion of those cells displaying antibodies with desired antigen binding characteristics, while secreted antibodies facilitate identification of antibodies having desired biological function(s).12-24-2009
20090307789TRANSGENIC MOLLUSK AND METHOD FOR PRODUCING THE SAME - A transgenic mollusk which can express a desired foreign gene, and a method for producing the same are disclosed. The mollusk is a transgenic mollusk into which a desired foreign gene (excluding a gene giving resistance to a virus) is introduced, which expresses the foreign gene. This transgenic mollusk can be produced by microinjecting into gonad of male and/or female of mollusk a recombinant vector into which a desired foreign gene to be introduced or a nucleic acid containing the foreign gene is inserted; crossing the male and female to produce individuals of first generation; and selecting therefrom (an) individual(s) which express(es) the desired gene.12-10-2009
20090307788RIBOZYME MEDIATED STABILIZATION OF POLYNUCLEOTIDES - The present invention relates to the production of novel, recombinant polynucleotides comprising the GIR1 ribozyme, or a variant thereof, vectors comprising such polynucleotides and recombinant host cells comprising such polynucleotides and/or such vectors. The invention furthermore relates to the use of said polynucleotides in the treatment of an individual suffering from a disease associated with or caused by instability of a transcript of said second subsequence such as cancer, cachexia, α-Thallasemia or leukaemia.12-10-2009
20080313752Method for Differentiating Mesenchymal Stem Cells Into Steroid-Producing Cells - To control the differentiation of mesenchymal stem cells into steroid hormone producing cells. Mesenchymal stem cells can be differentiated into steroid hormone-producing cells by being stimulated by a transcriptional factor (SF-1), preferably by the transcriptional factor (SF-1) and cAMP. The present invention is a method for differentiating mesenchymal stem cells into steroid hormone producing cells, comprising stimulating the mesenchymal stem cells by the transcriptional factor (SF-1). The mesenchymal stem cells may be further stimulated by cAMP.12-18-2008
20120192297SCREENING METHOD UTILIZING THALIDOMIDE-TARGETING FACTOR - With an aim to provide means for developing a compound devoid of teratogenicity but retaining beneficial actions, a screening method for a non-teratogenic substance comprising bringing a test substance into contact with cereblon or a fragment of cereblon, evaluating the bindability of the test substance with cereblon or the fragment of cereblon, and selecting a test substance that does not bind to cereblon or the fragment of cereblon or a test substance exhibiting lower bindability with cereblon or the fragment of cereblon than does thalidomide is provided.07-26-2012
20120192296PREPARATION OF ISOLATED AGONIST ANTI-EDAR MONOCLONAL ANTIBODIES - The present invention concerns the preparation of substantially purified agonist anti-EDAR monoclonal antibodies or isolated monoclonal antibody fragments or antigen binding portions or fragments thereof. The invention further relates to isolated agonist anti-EDAR monoclonal antibodies or isolated monoclonal antibody fragments or antigen binding portions or fragments thereof as well as their use in the treatment of X-linked hypohidrotic ectodermal dysplasia and tooth agenesis. The invention also relates to a pharmaceutical composition comprising said isolated agonist anti-EDAR monoclonal antibodies or isolated monoclonal antibody fragments or antigen binding portions or fragments thereof and to a method of treating X-linked hypohidrotic ectodermal dysplasia and tooth agenesis. Finally, the present invention concerns a pharmaceutical kit comprising said isolated agonist anti-EDAR monoclonal antibodies or isolated monoclonal antibody fragments or antigen binding portions or fragments thereof.07-26-2012
20090094708Vitamin K Epoxide Recycling Polypeptide VKORC1, a Therapeutic Target of Coumarin and Their Derivatives - The invention relates to a novel polypeptide vitamin K epoxide recycling polypeptide (VKORC1) as a target for coumarin and its derivatives. The invention further provides methods for identifying coumarin derivatives, and also claims VKORC1 polypeptides and VKORC1 nucleic acids containing a sequence abnormality associated with a VKORC1 associated deficiency such as warfarin resistance, wherein the VKORC1 polypeptides and VKORC1 nucleic acids can be used for diagnosing these deficiencies. Moreover, the invention relates to methods for identifying coumarin derivatives usable in pest control of rodents.04-09-2009
20080307536Voltage-Gated, Ph-Sensitive Anion Channel And Its Novel Splice Variant Involved In Taste Sensation - The invention provides a novel splice-variant of the ClC-4 protein, termed ClC-4A. ClC-4A is expressed in taste bud cells and is involved in sour taste perception. The invention provides ClC-4A polynucleotides and ClC-4A polypeptides, vectors, host cells and ClC-4A specific antibodies as well as designing high potency taste stimuli, determining taste preferences in animals, developing breed-specific foods, and modifying the taste of foods and medications.12-11-2008
20130061341MEGANUCLEASE VARIANTS CLEAVING A DNA TARGET SEQUENCE FROM A XP GENE AND USES THEREOF - An I-CreI variant which has at least two substitutions, one in each of the two functional subdomains of the LAGLIDADG (SEQ ID NO: 229) core domain situated from positions 26 to 40 and 44 to 77 of I-CreI, said variant being able to cleave a DNA target sequence from a xeroderma pigmentosum gene. Use of said variant and derived products for the prevention and the treatment of Xeroderma pigmentosum.03-07-2013
20090271881MEGANUCLEASE VARIANTS CLEAVING A DNA TARGET SEQUENCE FROM A RAG GENE AND USES THEREOF - An I-CreI variant, wherein one of the I-CreI monomers has at least two substitutions, one in each of the two functional subdomains of the LAGLIDADG core domain situated respectively from positions 26 to 40 and 44 to 77 of I-CreI, said variant being able to cleave a DNA target sequence from a RAG gene. Use of said variant and derived products for the prevention and the treatment of a SCID syndrome associated with a mutation in a RAG gene.10-29-2009
20090055941Novel Neural Cell Specific Promoter And Baculovirus And Method For Gene Delivery - There is provided a novel hybrid promoter region that utilizes a neural specific promoter and an enhancer element, in one embodiment from a viral promoter, located upstream or downstream of the neural-specific promoter. The novel promoter can be used to create a viral vector, including a baculovirus vector, useful for gene delivery to neural cells.02-26-2009
20120117673GENETIC ENCRYPTION - The present invention relates to a method to engineer either the genome of a genetically modified organism, other bioengineered reagent, or in vitro translation system for protein synthesis from specific protein-coding genes so that the protein-coding genes so engineered can only produce proteins with an intended structure when translated within the context of that specifically engineered GMO or in vitro translation system. It also relates to nucleic acids for use in such GMOs or translation systems.05-10-2012
20130067608COLON CANCER TARGETS AND USES THEREOF - The present invention provides a method for diagnosing and detecting diseases associated with colon. The present invention provides one or more proteins or fragments thereof, peptides or nucleic acid molecules differentially expressed in colon diseases (CCAT) and antibodies binds to CCAT. The present invention provides that CCAT is used as targets for screening agents that modulates the CCAT activities. Further the present invention provides methods for treating diseases associated with colon.03-14-2013
20130067607MEGANUCLEASE VARIANTS CLEAVING A DNA TARGET SEQUENCE FROM A RAG GENE AND USES THEREOF - An I-CreI variant, wherein one of the I-CreI monomers has at least two substitutions, one in each of the two functional subdomains of the LAGLIDADG core domain situated respectively from positions 26 to 40 and 44 to 77 of I-CreI, said variant being able to cleave a DNA target sequence from a RAG gene. Use of said variant and derived products for the prevention and the treatment of a SCID syndrome associated with a mutation in a RAG gene.03-14-2013
20110023155NOVEL DNA FRAGMENT AND USE THEREOF - The invention relates to a DNA consisting of the nucleotide sequence shown in SEQ ID NO: 1, or a nucleotide sequence the same or substantially the same as a partial nucleotide sequence thereof containing at least one HRE consensus sequence, which transiently has a transcription promoting activity in a vascular endothelial cell-specific manner in a hypoxic state, or a vector containing a promoter containing the DNA, and the like. The prophylaxis and/or treatment, as well as diagnosis, of acute ischemic diseases are enabled by connecting a prophylactic and/or therapeutic gene or a reporter gene to the downstream of the vector and administering same to mammals.01-27-2011
20120198578VIRAL ASSAY - The present invention relates to an assay for detecting virus, in particular an assay for detecting viral replication in a tissue sample. The invention also relates to methods of determining the susceptibility of an animal to a virus, and methods of breeding animals with decreased susceptibility to a virus.08-02-2012
20090013421Genomic DNA fragments containing regulatory and coding sequences for the B2-subunit of the neuronal nicotinic acetylcholine receptor and transgenic animals made using these fragments or mutated fragments - Several genes encoding subunits of the neuronal nicotinic acetylcholine receptors have been cloned and regulatory elements involved in the transcription of the ∝:2 and ∝:7-subunit genes have been described. Yet, the detailed mechanisms governing the neuron-specific transcription and the spatio-temporal expression pattern of these genes remain largely uninvestigated. The β2-subunit is the most widely expressed neuronal nicotinic receptors subunit in the nervous system. We have studied the structural and regulatory properties of the 5′ sequence of this gene. A fragment of 1163 bp of upstream sequence is sufficient to drive the cell-specific transcription of a reporter gene in both transient transfection assays and in transgenic mice. Deletion analysis and site-directed mutagenesis of this promoter reveal two negative and one positive element. The positively acting sequence includes one functional E-box. One of the repressor elements is located in the transcribed region and is the NRSE/RE1 sequence already described in promoters of neuronal genes.01-08-2009
20080295190Chinese hamster apoptosis-related genes11-27-2008
20110283373MUTANT PROTEASE BIOSENSORS WITH ENHANCED DETECTION CHARACTERISTICS - A polynucleotide encoding a biosensor polypeptide comprising a modified circularly-permuted thermostable luciferase and a linker linking the C-terminal portion of the thermostable luciferase to the N-terminal portion of the thermostable luciferase. The modified circularly-permuted thermostable luciferase is modified relative to a parental circularly-permuted thermostable luciferase. The linker contains a sensor region capable of interacting with a target molecule in a cell. The modified circularly-permuted thermostable luciferase has an enhanced response after interaction of the biosensor with the target molecule relative to the parental circularly-permuted thermostable luciferase in the presence of the target molecule. Alternatively, the modified circularly-permuted thermostable luciferase has an enhanced response after interaction of the biosensor with the target molecule relative to the modified circularly-permuted thermostable luciferase in the absence of the target molecule.11-17-2011
20100275280METHOD FOR IDENTIFYING, EXPANDING AND REMOVING ADULT STEM CELLS AND CANCER STEM CELLS - The invention relates to the fields of biochemistry, pharmacy and oncology. The invention particularly relates to the use of novel stem cell markers for the isolation of stem cells. The invention further relates to the obtained stem cells and their use in for example research or treatment, for example, for the preparation of a medicament for the treatment of damaged or diseased tissue.10-28-2010
20090038022IGF-1 Novel peptides - The present invention relates to novel polypeptide constructs based on peptides derived from Insulin-like Growth Factor I (IGF-1). The invention also relates to novel uses for IGF-1-derived peptides, particularly for the prevention and treatment of diseases involving regulation of cellular growth or differentiation, regeneration and tissue repair.02-05-2009
20110289609Neurotransmitter Sensors and Methods of Using the Same - Neurotransmitter biosensors are disclosed, including YbeJ-based glutamate binding biosensors, comprising a neurotransmitter binding domain conjugated to donor and fluorescent moieties that permit detection and measurement of Fluorescence Resonance Energy Transfer upon binding neurotransmitter. Such biosensors are useful for the detection of neurotransmitter concentrations in vivo and in culture.11-24-2011
20110296543NUCLEIC ACIDS AND PROTEINS AND METHODS FOR MAKING AND USING THEM - The invention provides polypeptides, including enzymes, structural proteins and binding proteins, polynucleotides encoding these polypeptides, and methods of making and using these polynucleotides and polypeptides. Polypeptides, including enzymes and antibodies, and nucleic acids of the invention can be used in industrial, experimental, food and feed processing, nutritional and pharmaceutical applications, e.g., for food and feed supplements, colorants, neutraceuticals, cosmetic and pharmaceutical needs. Polypeptides of the invention can be used in food processing, brewing, bath additives, alcohol production, peptide synthesis, enantioselectivity, hide preparation in the leather industry, waste management and animal degradation, silver recovery in the photographic industry, medical treatment, silk degumming, biofilm degradation, biomass conversion to a biofuel (e.g., a bioethanol, biomethanol, biopropanol or biobutanol, a biodiesel, etc.), biodefense, antimicrobial agents and disinfectants, personal care and cosmetics, biotech reagents, in corn wet milling and pharmaceuticals such as digestive aids and anti-inflammatory (anti-phlogistic) agents.12-01-2011
20100269182LEXA-BASED CHEMICAL-INDUCIBLE GENE EXPRESSION SYSTEM FOR USE IN TRANSGENIC ANIMALS - The present invention relates generally to chemical-inducible system and to methods of use in transgenic animals. More specifically, the present invention relates to a chimeric transcription factor that binds to a ligand and functions in ligand-dependent manner to induce expression of genes of interest under the control of a synthetic operator-promoter sequence. The expression of genes of interest can be tightly controlled by adding or removing the ligand.10-21-2010
20100169993Ligand-regulable transactivation systems, methods of use thereof, methods of detecting estrogen receptor ligands, and methods of differentiating estrogen receptor ligand agonists and antagonists - Briefly described, embodiments of this disclosure include ligand-regulable transactivation systems, methods of producing ligand-regulable transactivation systems, methods of using ligand-regulable transactivation systems, reporter polynucleotides, method of producing reporter polynucleotides, activator fusion proteins, methods of producing activator fusion proteins, methods of regulating gene expression in vitro and in vivo for gene therapy, methods of screening estrogen receptor modulators with therapeutic treatments (e.g., anticancer, antiosteoporosis, and hormone replacement treatments), method of screening compounds (e.g., drugs and environmental pollutants) for the estrogenic effect, methods of evaluating the estrogen receptor pathway under different pathological conditions are provided, and the like.07-01-2010
20100169992FGFR4 ANTIBODIES - The present invention relates to FGFR4 antibodies including fragments or derivatives thereof and the polynucleotides encoding the antibodies. Expression vectors and host cells comprising the polynucleotides are provided. Further, the invention refers to pharmaceutical compositions comprising the FGFR4 antibodies and methods for the treatment, prevention or diagnosis of disorders associated with FGFR4 expression.07-01-2010
20100169991Biopesticide comprising insect belonging to family coccinellidae - Disclosed is a biopesticide utilizing an insect belonging to the family Coccinelidae, which has excellent durability of effect, which can control a insect pest effectively, and which has little influence on an ecosystem. An insect belonging to the family Coccinelidae having abnormality in the wing formation can be produced by suppressing the expression of a vestigial gene and/or a scalloped gene in the insect.07-01-2010
20100011455STEM CELL GENE TARGETING - The invention provides a method for generating a transgenic eukaryotic cell population having a modified human Rosa26 locus, which method includes introducing a functional DNA sequence into the human Rosa26 locus of starting eukaryotic cells. Also provided are targeting vectors useful in the method, as well as a cell population and a transgenic non-human animal comprising a modified human Rosa26 locus. Finally, the invention provides an isolated DNA sequence corresponding to the human Rosa26 locus.01-14-2010
20100269183MICRO-RNAS THAT CONTROL MYOSIN EXPRESSION AND MYOFIBER IDENTITY - The present invention relates to the identification of two microRNAs, miR-499 and miR-208b, that repress fast skeletal muscle contractile protein genes. Expression of miR-499 and/or miR-208b can be used to repress fast fiber genes and activate slow fiber genes in the treatment of musculoskeletal disorders. Inhibition of miR-499 and/or miR-208b is proposed as a treatment for cardiac hypertrophy, myocardial infarction, and/or heart failure. Pharmaceutical compositions comprising antagonists and agonists of miR-499 and miR-208b function are also disclosed.10-21-2010
20090288181Transgenic animals for analyzing CYP3A4 cytochrome P450 gene regulation - The invention relates to the generation of non-human transgenic animals comprising a reporter construct for producing a detectable amount of a reporter molecule operably linked to a transcriptional regulatory nucleic acid molecule from the human CYP3A4 gene located between the initiation of transcription site of the gene and a position located 13,000 nucleotides upstream from the site. The invention also relates to the use of these animals for determining the effect of a compound, particularly, but not exclusively, a xenobiotic or steroid, on the regulation of expression of the CYP3A4 gene in a human.11-19-2009
20090178151NUCLEIC ACID ENCODING A NOVEL PROSTAGLANDIN RECEPTOR PROTEIN AND METHODS OF USE THEREOF - Described herein is a novel member of the prostanoid receptor family, a guinea pig prostaglandin D2 receptor. Described are the receptor, the nucleic acid that encodes it, and various uses for both.07-09-2009
20110219464LUNG DISEASE TARGETS AND USES THEREOF - The present invention provides a method for diagnosing and detecting diseases associated with lung. The present invention provides one or more proteins or fragments thereof, peptides or nucleic acid molecules differentially expressed in lung cancer (LCAT) and antibodies binds to LCATs. The present invention provides that LCATs are used as targets for screening agents that modulates the LCAT activities. Further the present invention provides methods for treating diseases associated with lung.09-08-2011
20090126034Environmentally Stable Sensors and Methods of Using the Same - Environmentally stable biosensors are disclosed, which comprise a ligand binding domain from a thermophilic organism conjugated to donor and fluorescent moieties that permit detection and measurement of Fluorescence Resonance Energy Transfer upon ligand binding. Such biosensors demonstrate enhanced acid-, thermal- and chemical stability as compared to sensors constructed using protein domains from mesophilic organisms.05-14-2009
20120110685MODULAR DNA-BINDING DOMAINS AND METHODS OF USE - The present invention refers to methods for selectively recognizing a base pair in a DNA sequence by a polypeptide, to modified polypeptides which specifically recognize one or more base pairs in a DNA sequence and, to DNA which is modified so that it can be specifically recognized by a polypeptide and to uses of the polypeptide and DNA in specific DNA targeting as well as to methods of modulating expression of target genes in a cell.05-03-2012
20090151013Modified ES cells and ES cell-specific genes - The invention concerns modified avian ES cells, specifically expressing an exogenous gene when they have a pluripotent character. The invention also concerns a nucleic acid and a polypeptide specifically expressed in pluripotent avian cells, and methods for detecting the pluripotent character of cells using said nucleic acid and polypeptide.06-11-2009
20110197291Endoplasmic Reticulum Localization Signals - The invention relates to cellular localization signals. In particular, the invention relates to endoplasmic reticulum localization signals in monomeric or multimeric form. The localization signals are utilized as research tools or are linked to therapeutics. Disclosed are methods of making and using polypeptides and modified polypeptides as signals to localize therapeutics, experimental compounds, peptides, proteins and/or other macromolecules to the endoplasmic reticulum of eukaryotic cells. The polypeptides of the invention optionally include linkage to reporters, epitopes and/or other experimental or therapeutic molecules. The invention also encompasses polynucleotides encoding the localization signals and vectors comprising these polynucleotides.08-11-2011
20100115639ANTIBODIES INHIBITING C-MET DIMERIZATION AND USES THEREOF - A process for the selection of anti c-Met antibodies capable of inhibiting both ligand-dependent and ligand-independent activation of c-Met, wherein said process is based on the inhibition of the c-Met dimerization. The present invention also concerns such antibodies and compositions comprising antibodies for the preparation of a medicament to treat cancer including diagnosis process and kits.05-06-2010
20110197292Delivery method - The present invention relates, in general, to RNA silencing and, in particular, to a method of effecting targeted delivery of an RNA silencing moiety using a targeting moiety that binds to a cell surface receptor and mediates internalization of the RNA silencing moiety to be accessible to Dicer. Also provided is a chimeric nucleic acid molecule comprised of a targeting moiety and an RNA silencing moiety, wherein the targeting moiety is an aptamer and the RNA silencing moiety comprises a Dicer substrate.08-11-2011
20100281552SYNTHETIC OPLOPHORUS LUCIFERASES WITH ENHANCED LIGHT OUTPUT - A polynucleotide encoding a modified luciferase polypeptide. The modified luciferase polypeptide has at least 60% amino acid sequence identity to a wild-type 11-04-2010
20090094707Method for Producing Polyunsaturated Long-Chain Fatty Acids in Transgenic Organisms - The invention relates to a method for producing polyunsaturated fatty acids in an organism, according to which nucleic acids coding for polypeptides with an acyl-CoA:lysophospholipid-acyltransferase activity am introduced into the organism. Advantageously, said nucleic acid sequences can be expressed in the transgenic organism optionally together with other nucleic acid sequences coding for polypeptides of the fatty acid or lipid metabolism. The invention also relates to the inventive nucleic acid sequences, nucleic acid constructs containing the inventive nucleic acid sequences, vectors containing the inventive nucleic acid sequences and/or the nucleic acid constructs, and transgenic organisms containing said nucleic acid sequences, nucleic acid constructs and/or vectors. The invention further relates to oils, lipids and/or fatty acids produced according to the inventive method, and to the use of the same.04-09-2009
20100088775METHODS OF MODULATING EPITHELIAL-MESENCHYMAL TRANSITION AND MESENCHYMAL-EPITHELIAL TRANSITION IN CELLS AND AGENTS USEFUL FOR THE SAME - The present invention relates generally to the fields of treatment, prophylaxis and diagnosis of cell-based and fibrotic conditions in animals including mammals. More particularly, the present invention contemplates the use of agents which modulate epithelial-mesenchymal transition (EMT) processes and mesenchymal-epithelial transition (MET) processes and hence are useful in the treatment of a range of conditions including inhibiting metastasis of solid tumors and the development of fibrosis, treating metastatic disease and in promoting wound healing. Diagnostic protocols to assess EMT and MET or its stage of development also form part of the present invention. The EMT and MET modulating agents are also useful in regulating gene expression and, hence, represent useful therapeutic and research tools.04-08-2010
20100088776PROCESSES FOR PRODUCING POLYUNSATURATED FATTY ACIDS IN TRANSGENIC ORGANISMS - The present invention relates to polynucleotides from 04-08-2010
20100088774CHARACTERIZATION OF GRANULOCYTIC EHRLICHIA AND METHODS OF USE - The present invention relates, in general, to granulocytic ehrlichia (GE) proteins. In particular, the present invention relates to nucleic acid molecules coding for GE S2, S7, S22, S23, C6.1, C6.2, S11, E8, E46#1, and E46#2 proteins; purified GE S2, S7, S22, S23, C6.1, C6.2, S11, E8, E46#1, and E46#2 proteins and polypeptides; recombinant nucleic acid molecules; cells containing the recombinant nucleic acid molecules; antibodies having binding affinity specifically to GE S2, S7, S22, S23, C6.1, C6.2, S11, E8, E46#1, and E46#2 proteins and polypeptides; hybridomas containing the antibodies; nucleic acid probes for the detection of nucleic acids encoding GE S2, S7, S22, S23, C6.1, C6.2, S11, E8, E46#1, and E46#2 proteins; a method of detecting nucleic acids encoding GE S2, S7, S22, S23, C6.1, C6.2, S11, E8, E46#1, and E46#2 proteins or polypeptides in a sample; kits containing nucleic acid probes or antibodies; bioassays using the nucleic acid sequence, protein or antibodies of this invention to diagnose, assess, or prognose a mammal afflicted with ehrlichiosis; therapeutic uses, specifically vaccines comprising S2, S7, S22, S23, C6.1, C6.2, S11, E8, E46#1, and E46#2 proteins or polypeptides or nucleic acids; and methods of preventing or inhibiting ehrlichiosis in an animal.04-08-2010
20110265196PENAEIDIN GENE PROMOTERS IN TIGER SHRIMP AND APPLICATIONS THEREOF - The present invention relates to new penaeidin gene promoters found in tiger shrimps and applications thereof. The promoters of the invention are useful for the development of transgenic shrimps and valuable for the shrimp culture industry.10-27-2011
20100100978RNAi MEDIATED EXPRESSION INHIBITION OF A CHOLINERGIC PROTEIN - The present invention relates to nucleic acid sequences producing at least one functional miRNA, at least one functional shRNA and/or at least one functional siRNA, said miRNA, shRNA or siRNA being designed to silence the expression of a gene that encodes a cholinergic protein. The present invention further relates to compositions and kits comprising such nucleic acid sequences as well as to uses thereof.04-22-2010
20100100975SILK PROTEINS - The present invention provides silk proteins, as well as nucleic acids encoding these proteins. The present invention also provides recombinant cells and/or organisms which synthesize silk proteins. Silk proteins of the invention can be used for a variety of purposes such as in the manufacture of personal care products, plastics, textiles, and biomedical products.04-22-2010
20090210953Identification of TRPML3 (MCOLN3) as a salty taste receptor and use in assays for identifying taste (salty) modulators and/or therapeutics that modulate sodium transport, absorption or excretion and/or aldosterone, and/or vasopressin production or release - The present invention relates to the elucidation that TRPML3 is involved in salty taste perception in primates including humans and likely other mammals and based thereon high-throughput mammalian and medium-throughput oocyte-based electrophysiological assays for identifying human TRPML3 modulators, preferably TRPML3 enhancers. Compounds that modulate TRPML3 function in the assay are expected to affect salty taste in humans. The inventive electrophysiological assays, such as the two-electrode voltage-clamp technique, facilitate the identification of compounds which specifically modulate human TRPML3. The assays of the invention provide a robust screen useful to detect compounds that facilitate (enhance) or inhibit TRPML3 function. Compounds that enhance or block TRPML3 channel activity should thereby modulate salty taste. In addition, these compounds may be used to regulate sodium excretion, urinary output and other biological functions relating to sodium levels and TRPML3 related functions.08-20-2009
20090249503ENZYME CONJUGATES FOR USE AS DETOXIFYING AGENTS - Disclosed are detoxifying enzyme conjugates, including conjugates of variants of such detoxifying enzymes. The detoxifying enzymes are preferably chlolinesterases, and more preferably, butyrylcholinesterase. Also disclosed are methods of making and using such conjugates.10-01-2009
20090276865Transgenic Drosophila line having fluorescent proteins with different colors - The present invention discloses a transgenic 11-05-2009
20080209581Induction of exon skipping in eukaryotic cells - Described is a method for at least in part decreasing the production of an aberrant protein in a cell, the cell comprising pre-mRNA comprising exons coding for the protein, by inducing so-called exon skipping in the cell. Exon-skipping results in mature mRNA that does not contain the skipped exon, which leads to an altered product of the exon codes for amino acids. Exon skipping is performed by providing a cell with an agent capable of specifically inhibiting an exon inclusion signal, for instance, an exon recognition sequence, of the exon. The exon inclusion signal can be interfered with by a nucleic acid comprising complementarity to a part of the exon. The nucleic acid, which is also herewith provided, can be used for the preparation of a medicament, for instance, for the treatment of an inherited disease.08-28-2008
20110173711eNos Mutations Useful for Gene Therapy and Therapeutic Screening - The present invention relates to new NOS variants or mutants which contain structural alterations in the site of Akt dependent phosphorylation. The altered NOS proteins or peptides, especially the human eNOS proteins or peptides, Akt proteins or polypeptides and their encoding nucleic acid molecules are useful as gene therapy agents for the treatment of diseases including post angioplasty restenosis, hypertension, atherosclerosis, heart failure, diabetes and diseases with defective angiogenesis. NOS proteins and peptides are also useful in methods of screening for agents which modulate NOS activity.07-14-2011
20110173710CHIMERIC MEGANUCLEASE ENZYMES AND USES THEREOF - The current invention relates to polypeptides encoding mutant I-DmoI derivatives with enhanced cleavage activity and altered sequence specificity and uses of these polypeptides. These polypeptides comprise at least the first I-DmoI domain, and the peptide sequence comprises the substitution of at least one of residues 15, 19 and/or 20 as well as at least one of the residues in positions 27, 29, 33, 35, 37, 75, 76, 77, 81 of the first I-DmoI domain.07-14-2011
20100100976METHODS AND COMPOSITIONS RELATED TO APOBEC-1 EXPRESSION - Disclosed are methods and compositions related to APOBEC-1.04-22-2010
20090288180NOVEL PROTEIN AND PRODUCTION PROCESS AND USE THEREOF - [Problems] To provide a polypeptide having a novel structure and showing an activity of inhibiting angiogenesis or an activity of inhibiting osteoclastogenesis, and to provide a recombinant protein by constructing a method of purifying the above protein. To provide an ingredient useful in designing remedies for tendinitis, rheumatoid arthritis, arthritis deformans, malignant tumor, etc.11-19-2009
20120144511MUTEINS OF THE PYRROLINE-5-CARBOXYLATE REDUCTASE 1 - The invention relates to muteins of the pyrroline-5-carboxylate reductase 1 (PYCR1), to nucleic acid molecules comprising a nucleotide sequence encoding such muteins, to methods of determining in a subject a predisposition of having an age related disorder associated with PYCR1, to methods of identifying a compound capable of modifying the expression of PYCR1 and methods of treating a subject having an age-related disorder associated with PYCR1. The invention further relates to a genetically modified animal and a method of modifying the expression of the PYCR1 gene in an animal.06-07-2012
20120297494COMPOSITIONS AND METHODS OF TREATMENT OF BLACK HEMOPHILIAC PATIENTS - It has been determined that most mutations in factor VIII occur in multiple haplotypes, not primarily in one haplo-type. The frequencies of mild, moderate, and severe hemophilia did not differ significantly according to the background haplo-type. The odds of having inhibitor were significantly higher among patients in the H3+H4 haplotype groups as compared to H1+H2 haplotype groups. This association appears to be independent of the mutation. The results indicate that white hemophiliacs should be treated with Kogenate®. However, it would clearly be of benefit to assess the haplotype of black hemophiliacs prior to prescribing the recombinant FVIII to be used for treatment. It is not essential to determine the actual mutations responsible for the hemophilia prior to prescribing the recombinant FVIII. Also described are transgenic human FVIII animal models.11-22-2012
20100287634Polypeptides Having Phytase Activity and Polynucleotides Encoding Same - The invention relates to 11-11-2010
20100005536Promoter for Introducing a Gene into a Lymphocyte or Blood Cell and Application Thereof - It is intended to provide a promoter for inducing expression selectively and strongly in an immunocompetent cell and/or a blood cell such as a lymphocyte. In the invention, the object was achieved by finding that HHV6 MIE promoter, HHV7 MIE promoter and HHV7 U95 promoter unexpectedly induce a specific expression in an immunocompetent cell and/or a blood cell such as a T lymphocyte. By utilizing the promoters, a selective delivery of a DNA vaccine or the like can be realized.01-07-2010
20090265796Adeno-associated virus vectors - The invention provides an isolated and purified DNA molecule comprising at least one DNA segment, a biologically active subunit or variant thereof, of a circular intermediate of adeno-associated virus, which DNA segment confers increased episomal stability, persistence or abundance of the isolated DNA molecule in a host cell. The invention also provides a composition comprising at least two adeno-associated virus vectors.10-22-2009
20090265797Novel Anti-IGF-IR Antibodies and Uses Thereof - The present invention relates to novel antibodies capable of binding specifically to the human insulin-like growth factor I receptor (IGF-IR). The invention likewise comprises the use of these antibodies as a medicament for the prophylactic and/or therapeutic treatment of cancers overexpressing IGF-IR, stimulated either by IGF1 and/or IGF2, or any pathology connected with the overexpression of said receptor as well as in processes or kits for diagnosis of illnesses connected with the overexpression of the IGF-IR and/or the IGF-I/Insulin hybrid receptor.10-22-2009
20080289055MELANOMA ANTIGENS AND THEIR USE IN DIAGNOSTIC AND THERAPEUTIC METHODS - The present invention provides a nucleic acid sequence encoding a melanoma antigen recognized by T lymphocytes, designated MART-1. This invention further relates to bioassays using the nucleic acid sequence, protein or antibodies of this invention to diagnose, assess or prognoses a mammal afflicted with melanoma or metastata melanoma. This invention also provides immunogenic peptides derived from the MART-1 melanoma antigen and a second melanoma antigen designated gp100. This invention further provides immunogenic peptides derived from the MART-1 melanoma antigen or gp100 antigen which have been modified to enhance their immunogenicity. The proteins and peptides provided can serve as an immunogen or vaccine to prevent or treat melanoma.11-20-2008
20100275281Multiple Inducible Gene Regulation System - The present invention relates to the field of biotechnology or genetic engineering. More specifically, the present invention relates to a multiple inducible gene regulation system that functions within cells to simultaneously control the quantitative expression of multiple genes.10-28-2010
20100005535Compositions And Methods For Generating Transgenic Animals - The present invention provides methods of altering gene expression of embryos to provide compositions and methods for efficient generation of transgenic animals. In particular, the present invention provides compositions and methods for generating germ-line transgenic animals by direct injection of nucleic acid molecules into animals.01-07-2010
20080289057SPERM FACTOR SEQUENCES - A nucleic acid sequence, including an isolated, purified or recombinant nucleic acid sequence, includes: 11-20-2008
20080271166I-Dmoi Derivatives with Enhanced Activity at 37oC and Use Thereof - I-DmoI derivatives with enhanced cleavage activity at 37° C., said mutant comprising a sequence of a mutant of a I-DmoI endonuclease or a chimeric 5 derivative thereof including at least the first I-DmoIdomain, said sequence comprising the sub-situation of at least: (i) one of the residues in positions 4, 20, 49, 52, 92, 94 and/or 95 of said first I-DmoIdomain, and/or (ii) one of the residues in positions 101, 102, and/or 109 of the linker or the beginning of the second domain of I-DmoI, if present. 10 Polynucleotide encoding said derivatives, cell, animal or plant comprising said polynucleotide and use thereof for isolating meganucleases with new DNA target specificity.10-30-2008
20080263688Hafnia Phytase - The present invention relates to isolated polypeptides having phytase activity and isolated polynucleotides encoding the polypeptides. The polypeptides are related to a phytase derived from 10-23-2008
20110271358HUMAN ANTI-PD-1, PD-L1, AND PD-L2 ANTIBODIES AND USES THEREFOR - The present invention is based, in part, on the identification of novel human anti-PD-1, PD-L1, and PD-L2 antibodies. Accordingly, the invention relates to compositions and methods for diagnosing, prognosing, and treating conditions that would benefit from modulating PD-1, PD-L1, and/or PD-L2 activity (e.g., persistent infectious diseases, autoimmune diseases, asthma, transplant rejection, inflammatory disorders and tumors) using the novel human anti-PD-1, PD-L1, and PD-L2 antibodies described herein.11-03-2011
20090138977Pancreatic cancer targets and uses thereof - The present invention provides a method for diagnosing and detecting diseases associated with pancreas. The present invention provides one or more proteins or fragments thereof, peptides or nucleic acid molecules differentially expressed in pancreatic diseases (PCAT) and antibodies binds to PCAT. The present invention provides that PCAT is used as targets for screening agents that modulates the PCAT activities. Further, the present invention provides methods for treating diseases associated with pancreas.05-28-2009
20090178149Polyamine Sensors and Methods of Using the Same - Polyamine biosensors are disclosed, including putrescine binding biosensors, comprising a polyamine binding domain conjugated to donor and fluorescent moieties that permit detection and measurement of Fluorescence Resonance Energy Transfer upon binding polyamine. Such biosensors are useful for the detection of polyamine concentrations in vivo and in culture.07-09-2009
20090144839METHODS AND COMPOSITIONS FOR DETECTING AND TREATING RETINAL DISEASES - The invention discloses multiple genes related to age-related macular degeneration (AMD) and/or phagocytosis by RPE cells of the eye, and methods and compositions for detecting and treating AMD and other retinal degenerative conditions based on these phagocytosis-related and/or AMD-related genes. Also provided are animal models useful for testing therapeutic compounds and treatment protocols for AMD, and gene arrays including polymorphic variants of phagocytosis-related and/or AMD-related genes, useful for genetic screening of nucleic acid samples from subjects to obtain profiles of polymorphic variant sequences in a plurality of genes associated with AMD.06-04-2009
20090019559Nucleic Acid - The invention relates to nucleic acid derived from 01-15-2009
20110225663METHOD FOR PRODUCING EUKARYOTIC ORGANISMS WITH ENHANCED PATHOGEN RESISTANCE AND/OR RESISTANCE TO STRESS AND EUKARYOTIC TRANSGENIC ORGANISMS WITH ENHANCED PATHOGEN RESISTANCE AND/OR RESISTANCE TO STRESS - A method for producing an eukaryotic organism having at least one of enhanced pathogen resistance and resistance to stress includes expressing in a cytosol of the eukaryotic organism a glucose-6-phosphate dehydrogenase with an increased NADPH tolerance compared to an endogenous cytosolic glucose-6-phosphate dehydrogenase and at least one of reducing, eliminating and suppressing an activity of the endogenous cytosolic glucose-6-phosphate dehydrogenase.09-15-2011
20110225662FEMALE SPECIFIC INSECT EXPRESSION SYSTEM - The present invention provides an insect expression system that may be used to provide biological control of pest insects and control transmission of infectious diseases transmitted to the human population by insects.09-15-2011
20110145939MODIFIED ARTHROPOD AND METHOD OF USE - A modified arthropod, an arthropod-modifying bacterium, and use thereof as an agent for control of diseases transmitted by arthropods, particularly mosquitoes, is provided. More specifically, an isolated arthropod-adapted 06-16-2011
20110145940TAL EFFECTOR-MEDIATED DNA MODIFICATION - Materials and Methods related to gene targeting (e.g., gene targeting with transcription activator-like effector nucleases; “TALENS”) are provided.06-16-2011
20120079613Homeobox Transcription Factor BSX and Uses Thereof for Treating Diseases, in Particular Obesity - The present invention relates to the human homeobox transcription factor Bsx protein, nucleic acids encoding for said protein, vectors and cells comprising the nucleic acids, antibodies directed against Bsx, and methods for identifying compounds binding to Bsx, as well as to the use of proteins, nucleic acids, vectors, cells, and interacting compounds for treating obesity and related diseases.03-29-2012
20090064352CREATING POULTRY AND OTHER ANIMALS RESISTANT TO VIRAL DISEASE - The invention is directed to genetically modified animals which are resistant to viral infections. Also provided are methods for creating animals which are resistant to viral infections.03-05-2009
20090055942Human Coagulation Factor VII Polypeptides - The present invention relates to novel human coagulation Factor Vila variants having substitutions of one or more amino acids at a position selected from the group consisting of position 172, 173, 175, 176, 177, 196, 197, 198, 199, 200, 203, 235, 237, 238, 239, 240, 286, 287, 288, 289, 290, 291, 292, 293, 294, 295, 297, 299, 319, 320, 321, 327, 341, 363, 364, 365, 366, 367, 370, 373 corresponding to amino acid positions of SEQ ID NO:1 and wherein said Factor VII polypeptide exhibits increased resistance to inactivation by an endogenous inhibitor of said FVII polypeptide relative to wild-type human FVIIa.02-26-2009
20080263687CHIMERIC RETINOID X RECEPTORS AND THEIR USE IN A NOVEL ECDYSONE RECEPTOR-BASED INDUCIBLE GENE EXPRESSION SYSTEM - This invention relates to the field of biotechnology or genetic engineering. Specifically, this invention relates to the field of gene expression. More specifically, this invention relates to a novel ecdysone receptor/chimeric retinoid X receptor-based inducible gene expression system and methods of modulating gene expression in a host cell for applications such as gene therapy, large-scale production of proteins and antibodies, cell-based high throughput screening assays, functional genomics and regulation of traits in transgenic organisms.10-23-2008
20110231942TIKI1 AND TIKI2, WNT INHIBITORS - This invention relates to Tiki1 and Tiki2 proteins and nucleic acids, cells expressing the same, and methods for identifying compounds that modulate Tiki1/2 activity for use in the treatment of osteoporosis or cellular proliferative disorders.09-22-2011
20090205059Methods, Compositions and Systems for Production of Recombinant Spider Silk Polypeptides - Disclosed are methods, compositions, and systems for transforming silkworms to produce spider silk and analogs of spider silk. In certain embodiments, the method may include inserting a DNA sequence coding for at least a portion of a spider silk fibroin polypeptide, or an analog of a spider silk fibroin polypeptide, positioned between at least a portion of the 5′ and 3′ ends of a silkworm fibroin gene to generate a fusion gene construct having a sequence that encodes for a polypeptide comprising both spider silk fibroin and silkworm silk fibroin sequences. In certain embodiments, the fused gene is able to replace a native gene present in the silkworm such that the transformed silkworm expresses a polypeptide comprising a spider silk fibroin polypeptide, or an analog thereof, and expresses significantly less of the native silkworm silk.08-13-2009
20100154070PiggyBac as a Tool for Genetic Manipulation and Analysis in Vertebrates - The present invention relates to transgenic vertebrate, including mammalian, cells, whose genomes comprise one or more elements of the piggyBac family transposon system. Transgenic non-human vertebrates, including transgenic non-human mammals, whose genomes comprise one or more elements of the piggyBac family transposon system, are also provided. Methods of making and using the cells and animals of the invention, including applications in the medical, veterinary, and agricultural fields, are additionally provided. The present invention also relates to kits useful for practicing such methods.06-17-2010
20090210952Compositions and Methods Related to Controlled Gene Expression Using Viral Vectors - Provided herein are methods and compositions related to viral vectors. Also provided herein are methods and compositions for the efficient transfection of a host, for example through the highly efficient lentivector delivery system, and for the exquisite control of the timing and level of expression of the transferred sequence of interest by the simple administration of a modulator to the host harboring the transferred sequence of interest. Also disclosed are methods of making transgenic mice and transgenic mice made using compositions and methods relating to viral vectors.08-20-2009
20090222938Therapeutic Target Molecules For The Development of Novel Medicaments for Degenerative Diseases - The present invention generally relates to the field of therapy, prophylaxis and diagnosis of degenerative diseases, in particular neurodegenerative diseases. Specifically, the present invention relates to genes and proteins, which are regulated in connection with chronic oxidative stress in cells and are applied for therapy, prophylaxis, and diagnosis of degenerative diseases, in particular neurodegenerative diseases. Additionally, the present invention relates to the use of genes and proteins, which are regulated in conjunction with chronic oxidative stress in cells, for the screening of candidate substances to identify prophylactic and/or therapeutic agents, which agents modulate the biologic activity of genes and/or proteins, which genes and/or proteins are activated in conjunction with chronic oxidative stress in cells. Further, the present invention relates to methods for diagnosis of degenerative diseases, in particular neurodegenerative diseases, and methods for identifying prophylactic and/or therapeutic agents, which agents modulate the biologic activity of genes and/or proteins, which genes and/or proteins are activated in conjunction with chronic oxidative stress in cells. Further, the present invention relates to kits performing the methods of diagnosis.09-03-2009
20090222937MEGANUCLEASE VARIANTS CLEAVING A DNA TARGET SEQUENCE FROM A XERODERMA PIGMENTOSUM GENE AND USES THEREOF - An I-CreI variant which has at least two substitutions, one in each of the two functional subdomains of the LAGLIDADG (SEQ ID NO: 229) core domain situated from positions 26 to 40 and 44 to 77 of I-CreI, said variant being able to cleave a DNA target sequence from a xeroderma pigmentosum gene. Use of said variant and derived products for the prevention and the treatment of Xeroderma pigmentosum.09-03-2009
20090205058GENETICALLY MODIFIED NON-HUMAN MAMMALS AND CELLS - Genetically modified mammals are described which lack the mannan binding lectin associated serine protease MASP-2, together with methods and constructs for their production. Such mammals are useful as models for disorders of the complement system, and in the identification of treatments for such disorders. Also described are mammals which lack the associated protein MAp19; such mammals may also lack MASP-2.08-13-2009
20090210954GENES - The present invention relates to two primordial germ cell-specific expressed genes, 08-20-2009
20090205060SESQUITERPENE SYNTHASES FROM PATCHOULI - The invention relates to sesquiterpene synthases from Patchouli plants (08-13-2009
20100162421Use of pleitrophin for preventing and treating pancreatic diseases and/or obesity and/or metabolic syndrome - The present invention discloses the protein pleitrophin secreted by the developing pancreas, and polynucleotides, which identify and encode this protein. The invention also relates to the use of these sequences in the diagnosis, study, prevention, and treatment of pancreatic diseases (e.g. diabetes), obesity, and/or metabolic syndrome.06-24-2010
20120246747RNA-INTERFERENCE BY SINGLE-STRANDED RNA MOLECULES - The present invention relates to sequence and structural features of single-stranded (ss)RNA molecules required to mediate target-specific nucleic acid modifications by RNA-interference (RNAi), such as target mRNA degradation and/or DNA methylation.09-27-2012
20100186103Isolation Of Novel AAV'S And Uses Thereof - The invention in some aspects relates to isolated nucleic acids, compositions, and kits useful for identifying adeno-associated viruses in cells. In some aspects, the invention provides kits and methods for producing somatic transgenic animal models using recombinant AAV (rAAV) to an animal having at least one transgene that expresses a small interfering nucleic acid or at least one binding site for a miRNA.07-22-2010
20100186102Methods and compositions for post-transcriptional gene silencing - An isolated double stranded ribonucleic acid (dsRNA) molecule that inhibits the expression of a target gene, the dsRNA comprising two strands of nucleotides wherein a first strand has a length of from 19 to 28 consecutive nucleotides and is substantially identical to a sequence in the target gene and wherein a second strand is substantially complementary to the first strand, and a binding moiety that binds a 3′ end of the first strand to a 5′ end of the second strand. An isolated double stranded ribonucleic acid molecule comprising a first strand of nucleotides that is substantially identical to SEQ ID NO: 3 and a second strand that is substantially complementary to the first.07-22-2010
20110107444NOVEL POLY(ADP-RIBOSE) POLYMERASE GENES - The invention relates to poly(ADP-ribose)polymerase (PARP) homologs which have an amino acid sequence which has 05-05-2011
20100192238ELONGASES AND METHODS FOR PRODUCING POLYUNSATURATED FATTY ACIDS IN TRANSGENIC ORGANISMS - The present invention relates to polynucleotides from 07-29-2010
20100192237Methods for Controlling Gene Expression Using Ta-Sira - The present invention is in the field of genetics, especially plant genetics, and provides agents capable of controlling gene expression. More specifically the inventions relates to methods for engineering ta-siRNA primary transcripts in order to target gene-of-interest (GOI) and control their expression. The invention further provides for a method for modulating transgenic expression by said engineered ta-siRNAs.07-29-2010
20100229252MEGANUCLEASE VARIANTS CLEAVING A DNA TARGET SEQUENCE FROM THE HUMAN HEMOGLOBIN BETA GENE AND USES THEREOF - An I-CreI variant, wherein one of the two I-CreI monomers has at least two substitutions, one in each of the two functional subdomains of the LAGLIDADG core domain situated respectively from positions 26 to 40 and 44 to 77 of I-CreI, said variant being able to cleave a DNA target sequence from the human beta globin gene. Use of said variant and derived products for the prevention and the treatment of pathological conditions caused by a mutation in the human beta globin gene (sickle cell disease, beta-thalassemia).09-09-2010
20100212033Novel ubiquitin lifases as therapeutic tragets - The present invention relates to the discovery, identification and characterization of nucleotides that encode novel substrate-targeting subunits of ubiquitin ligases. The invention encompasses nucleotides encoding novel substrate-targeting subunits of ubiquitin ligases: FBP1, FBP2, FBP3, FBP4, FBP5, FBP6, FBP7, FBP8, FBP9, FBP10, FBP11, FBP12, FBP13, FBP14, FBP15, FBP16, FBP17, FBP18, FBP19, FBP20, FBP21, FBP22, FBP23, FBP24, and FBP25, transgenic mice, knock-out mice, host cell expression systems and proteins encoded by the nucleotides of the present invention. The present invention relates to screening assays that use the novel substrate-targeting subunits to identify potential therapeutic agents such as small molecules, compounds or derivatives and analogues of the novel ubiquitin ligases which modulate activity of the novel ubiquitin ligases for the treatment of proliferative and differentiative disorders, such as cancer, major opportunistic infections, immune disorders, certain cardiovascular diseases, and inflammatory disorders. The invention further encompasses therapeutic protocols and pharmaceutical compositions designed to target ubiquitin ligases and their substrates for the treatment of proliferative disorders.08-19-2010
20100146651MEGANUCLEASE VARIANTS CLEAVING A DNA TARGET SEQUENCE FROM THE HPRT GENE AND USES THEREOF - An I-CreI variant or a single-chain derivative having at least one substitution in one of the two functional subdomains of the LAGLIDADG (SEQ ID NO: 153) core domain situated from positions 26 to 40 and 44 to 77 of I-CreI, and being able to cleave a DNA target sequence from the HPRT gene having a nucleotide sequence of SEQ ID NO: 1 to 14. Use of said variant for inducing a site-specific modification in the HPRT gene, for therapeutic (gene therapy of Lesch-Nyhan syndrome) or non-therapeutic purpose (engineering of transgenic animals and recombinant cell lines).06-10-2010
20100146650METHOD FOR GENERATING ACTIVE ANTIBODIES AGAINST A RESISTANCE ANTIGEN, ANTIBODIES OBTAINED BY SAID METHOD AND THEIR USES - The present invention relates to the use of a milled homogenate and/or a suspension and/or a cell lysate, stemming from a tumor resistant to at least one anti-tumoral compound in order to immunize and generate in vitro an antibody, or one of its functional fragments, directed against a tumoral antigen specifically expressed at the surface of said resistant tumor and being possibly involved in the resistance of said resistant tumor. More particularly, the present invention is directed to such antibodies obtained by applying the method, such as the antibodies 1A6, 1A9, 2E11, 3C11 and 3G7, as well as to their use for treating cancer.06-10-2010
20100154071FXDY5 MODULATORS FOR TREATING, DIAGNOSING, AND DETECTING CANCER - The invention provides, inter alia, methods for treating cancer, compositions for treating cancer, and methods and compositions for diagnosing and/or detecting cancer. In particular, the present invention provides compositions and methods for treating, diagnosing and detecting cancers associated with FXYD5 overexpression.06-17-2010
20100235933Kaspp (lrrk2) gene, its production and use for the detection and treatment of neurodegenerative disorders - The present invention refers to a newly discovered gene named KASPP for Kinase Associated with Parkinsonism with Pleiomorphic Pathology or alternatively named LRRK2 for Leucine-Rich Repeat Kinase 2, its production, biochemical characterization and use for the detection and treatment of neurodegenerative disorders, such as Parkinson disease (PD) including, without limitation, sporadic PD, Alzheimer disease (AD), amyotrophic lateral sclerosis (ALS), and other synucleinopathies and/or tauopathy as well as several polymorphisms and mutations in the KASPP/LRRK2 gene segregated with PD.09-16-2010
20100212034Method For Producing Unsaturated Omega-3-Fatty Acids In Transgenic Organisms - The present invention relates to nucleic acid sequences coding for polypeptides with ω-3-desaturase activity. The invention furthermore relates to nucleic acid constructs, vectors and organisms comprising at least one nucleic acid sequence according to the invention, at least one vector comprising the nucleic acid sequence and/or the nucleic acid constructs, and transgenic organisms comprise the abovementioned nucleic acid sequences, nucleic acid constructs and/or vectors.08-19-2010
20100146652XENOBIOTIC RELATED INDUCTION OF GENE EXPRESSION - An isolated nucleic acid molecule comprising a nucleotide sequence encoding a transcriptional enhancer of cytochrome P450 (P450) CYP3A4 production or expression, and uses of the nucleic acid molecule for screening compounds for xenobiotic induction of CYP3A4 expression in cells and animals.06-10-2010
20100218263TRANSGENIC MOLLUSK AND METHOD FOR PRODUCING THE SAME - A transgenic mollusk which can express a desired foreign gene, and a method for producing the same are disclosed. The mollusk is a transgenic mollusk into which a desired foreign gene (excluding a gene giving resistance to a virus) is introduced, which expresses the foreign gene. This transgenic mollusk can be produced by microinjecting into gonad of male and/or female of mollusk a recombinant vector into which a desired foreign gene to be introduced or a nucleic acid containing the foreign gene is inserted; crossing the male and female to produce individuals of first generation; and selecting therefrom (an) individual(s) which express(es) the desired gene.08-26-2010
20100138944Methods of Reducing Repeat-Induced Silencing of Transgene Expression and Improved Fluorescent Biosensors - Methods of avoiding repeat- and homology-induced silencing of transgenes are disclosed, in which transgene sequences are genetically altered to reduce the affects of gene silencing. FRET biosensors containing such genetic alterations for improved expression in cell lines and in vivo are disclosed.06-03-2010
20110023154SILKWORM GENOME EDITING WITH ZINC FINGER NUCLEASES - The present invention provides a genetically modified silkworm or cell comprising at least one edited chromosomal sequence. In particular, the chromosomal sequence is edited using a zinc finger nuclease-mediated editing process. The disclosure also provides zinc finger nucleases that target specific chromosomal sequences in the silkworm genome.01-27-2011
20100138945HUMANIZED ANTI-IL-6 ANTIBODIES - The present invention relates to novel chimeric, humanized or CDR-grafted anti-IL-6 antibodies, including isolated nucleic acids that encode at least one such anti-IL-6 antibody, vectors, host cells, transgenic animals or plants, and methods of making and using thereof, including therapeutic compositions, methods and devices.06-03-2010
20090282495NEUROTROPHIC FACTOR MANF AND USES THEREOF - The present invention generally relates to the field of treatment of neuronal disorders and more particularly to neurotrophic factor MANF and uses thereof. The present invention provides a pharmaceutical compound comprising MANF nucleic acid molecule, MANF protein or a functional fragment thereof for the treatment of a peripherial neuropathy including Alzheimer's disease, Parkinson's disease, epilepsy, drug addiction and ischemic brain injury.11-12-2009
20090328244METHODS AND REAGENTS FOR MOLECULAR CLONING - The present invention provides compositions, methods, and kits for covalently linking nucleic acid molecules. The methods include a strand invasion step, and the compositions and kits are useful for performing such methods. For example, a method of covalently linking double stranded (ds) nucleic acid molecules can include contacting a first ds nucleic acid molecule, which has a topoisomerase linked to a 3′ terminus of one end and has a single stranded 5′ overhang at the same end, with a second ds nucleic acid molecule having a blunt end, such that the 5′ overhang can hybridize to a complementary sequence of the blunt end of the second nucleic acid molecule, and the topoisomerase can covalently link the ds nucleic acid molecules. The methods are simpler and more efficient than previous methods for covalently linking nucleic acid sequences, and the compositions and kits facilitate practicing the methods, including methods of directionally linking two or more ds nucleic acid molecules.12-31-2009
20110067125METHOD FOR PRODUCING FOUNDER ANIMAL FOR REPRODUCING ANIMAL HAVING LETHAL PHENOTYPE CAUSED BY GENE MODIFICATION - An object of the present invention is to provide a method which constantly enables organ regeneration for the purpose of achieving organ regeneration with higher efficiency. It has been discovered that, in a blastocyst complementation method, a next generation is born when a deficiency in an organ, such as pancreas and kidney, is complemented by injection of ES cells into a generated blastocyst, and further discovered that a transgenic animal having a pancreas or a kidney thus complemented can transmit the phenotype to the next generation as a founder. This discovery has revealed that organ regeneration can be accomplished by using such a founder. Thus, the present invention achieved the above-described object.03-17-2011
20110067124DETECTION AND TREATMENT OF DRUG ASSOCIATED ANGIOEDEMA - The present invention relates to an in vitro method of diagnosing a drug-associated angioedema or a predisposition thereto in a subject being suspected to having developed or of having a predisposition to develop a drug-associated angioedema or in a subject being intended to be treated with a drug associated with the development of angioedema, the method comprising determining in a biological sample from said subject the presence or absence of a disease-associated mutation in a nucleic acid molecule regulating the expression of or encoding coagulation factor XII; wherein the presence of such a mutation is indicative of a drug-associated angioedema or a predisposition thereto.03-17-2011
20090260094Stearoyl-CoA Desaturase 4 Gene - The cloning of a fourth mouse SCD gene, mSCD4, as well as its corresponding cDNA and amino acid sequences are disclosed. Mouse SCD4 is expressed mainly in the heart tissue and synthesizes the bulk of monounsaturated fatty acids in the heart. The disclosure here enables new tools (e.g., nucleic acids, polypeptides, antibodies, vectors, recombinant cells, and transgenic and knock-out animals) for studying the function of various SCD isoforms and their connection to various disease conditions. New tools for converting saturated fatty acyl-CoA to monounsaturated acyl-CoA and for identifying SCD modulators including isoform-specific modulators are also enabled. In addition, given that accumulation of lipid in the heart (fatty heart) can have deleterious consequences, the present invention also provides a new prevention and treatment target for fatty heart as well as methods for screening candidate drugs.10-15-2009
20090320148OXYLIPINS FROM STEARIDONIC ACID AND GAMMA-LINOLENIC ACID AND METHODS OF MAKING AND USING THE SAME - Disclosed are novel oxylipins that are derived from γ-linolenic acid (GLA; 18:3n-6) and stearidonic acid (STA or SDA; 18:4n-3), and methods of making and using such oxylipins. Also disclosed is the use of such oxylipins in therapeutic and nutritional or cosmetic applications, and particularly as anti-inflammatory or anti-neurodegenerative compounds. Also disclosed are The invention novel ways of producing long chain polyunsaturated acid (LCPUF A)-rich oils and compositions that contain enhanced and effective amounts of SDA- and/or GLA-derived oxylipins.12-24-2009
20090178148Compositions and methods for modifying the content of polyunsaturated fatty acids in mammalian cells - The present invention features compositions (e.g., nucleic acids encoding fat-1, optionally and operably linked to a constitutively active or tissue-specific promoter or other regulatory sequence) and pharmaceutically acceptable formulations including nucleic acids encoding fat-1 or biologically active variants thereof and methods that can be used to effectively modify the content of PUFAs in animal cells (i.e., cells other than those of 07-09-2009
20090178150Novel Method for Generating Non-Human ES Animals - The present invention provides a method for generating non-human animals by transferring ES cells to three or four tetraploid embryos to produce chimeric embryos and implanting the chimeric embryos to a psudopregnant non-human animal.07-09-2009
20100223683Isolated Polynucleotide Sequence with IRES Activity - Provided herein is an isolated polynucleotide sequence with internal ribosome entry site (IRES) activity, which directs translation initiation in an insect expression system in a cap-independent manner. In particular, the invention relates to an isolated polynucleotide comprises the 5′ UTR of 09-02-2010
20090038023Lyase Enzymes, Nucleic Acids Encoding Them and Methods For Making and Using Them - This invention provides polypeptides having lyase activity, polynucleotides encoding these polypeptides, and methods of making and using these polynucleotides and polypeptides. In one aspect, the invention is directed to polypeptides having ammonia lyase activity, e.g., phenylalanine ammonia lyase, tyrosine ammonia lyase and/or histidine ammonia lyase activity, including thermostable and thermotolerant activity, and polynucleotides encoding these enzymes, and making and using these polynucleotides and polypeptides. The polypeptides of the invention can be used in a variety of pharmaceutical, agricultural and industrial contexts.02-05-2009
20090070890Product - The invention relates to tumor-specific binding proteins and all uses thereof. In particular, the invention relates to antibodies or antibody fragments specific for antigens or molecules on cancer cells (CD166) and to methods of use thereof. Binding proteins comprising specific heavy and light chain CDRs are disclosed wherein the binding protein shows a measurable or significant binding to breast cancer cell line MDA-MB 231 but shows insignificant or unmeasurable binding to granulocytes or peripheral blood lymphocytes (PBLs).03-12-2009
20100306865PENAEIDIN GENE PROMOTERS IN TIGER SHRIMP AND APPLICATIONS THEREOF - The present invention relates to new penaeidin gene promoters found in tiger shrimps and applications thereof. The promoters of the invention are useful for the development of transgenic shrimps and valuable for the shrimp culture industry.12-02-2010
20100313284MEANS AND METHODS FOR ELICITING AN IMMUNE RESPONSE - The invention provides means and methods for immunizing an animal against an antigen of interest, using stem cells, progenitor cells and/or dedifferentiated cells.12-09-2010
20110113497MONOCLONAL ANTIBODIES AGAINST GONADOTROPIN-RELEASING HORMONE RECEPTOR - Monoclonal antibodies against gonadotropin releasing hormone (GnRH) receptor induce cellular apoptosis of various cancer cells expressing this surface receptor. The monoclonal antibodies and their humanized forms, or fragments thereof, can serve as anti-cancer agents for the treatment of cancer in humans, and can function as analogs of GnRH to affect regulation of reproductive functions or fertility in humans.05-12-2011
20100313283USES OF GDNF AND GDNF RECEPTOR - GDNFRα, GDNFRα extracellular domain (ECD), GDNFRα variants, chimeric GDNFRα (e.g., GDNFRα immunoadhesin), and antibodies which bind thereto (including agonist and neutralizing antibodies) are disclosed. Various uses for these molecules are described, including methods to modulate cell activity and survival by response to GDNFRα-ligands, for example GDNF, by providing GDNFRα to the cell. Also provided are methods for using GDNFRα, GDNF, or agonists thereof, separately or in complex, to treat kidney diseases.12-09-2010
20110131671POLYMORPHISMS IN THE HUMAN GENE FOR CYTOCHROME P450 POLYPEPTIDE 2C8 AND THEIR USE IN DIAGNOSTIC AND THERAPEUTIC APPLICATIONS - The present invention relates to a polymorphic CYP2C8-polynucleotide. Moreover, the invention relates to genes or vectors comprising the polynucleotides of the invention and to a host cell genetically engineered with the polynucleotide or gene of the invention. Further, the invention relates to methods for producing molecular variant polypeptides or fragments thereof, methods for producing cells capable of expressing a molecular variant polypeptide and to a polypeptide or fragment thereof encoded by the polynucleotide or the gene of the invention or which is obtainable by the method or from the cells produced by the method of the invention. Furthermore, the invention relates to an antibody which binds specifically the polypeptide of the invention. Moreover, the invention relates to a transgenic non-human animal. The invention also relates to a solid support comprising one or a plurality of the above mentioned polynucleotides, genes, vectors, polypeptides, antibodies or host cells. Furthermore, methods of identifying a polymorphism, identifying and obtaining a prodrug or drug or an inhibitor are also encompassed by the present invention. In addition, the invention relates to methods for producing of a pharmaceutical composition and to methods of diagnosing a disease. Further, the invention relates to a method of detection of the polynucleotide of the invention. Furthermore, comprised by the present invention are a diagnostic and a pharmaceutical composition. Even more, the invention relates to uses of the polynucleotides, genes, vectors, polypeptides or antibodies of the invention. Finally, the invention relates to a diagnostic kit.06-02-2011
20130145487MEGANUCLEASE VARIANTS CLEAVING A DNA TARGET SEQUENCE FROM THE DYSTROPHIN GENE AND USES THEREOF - The invention relates to meganuclease variants which cleave a DNA target sequence from the human dystrophin gene (DMD), to vectors encoding such variants, to a cell, an animal or a plant modified by such vectors and to the use of these meganuclease variants and products derived therefrom for genome therapy, ex vivo (gene cell therapy) and genome engineering including therapeutic applications and cell line engineering. The invention also relates to the use of meganuclease variants for inserting therapeutic transgenes other than DMD at the dystrophin gene locus, using this locus as a safe harbor locus. The invention also relates to the use of meganuclease variants for using the dystrophin gene locus as a landing pad to insert and express genes of interest.06-06-2013
20100333221MUTATED HYPERTHERMOPHILIC PHOSPHOTRIESTERASES AND USES THEREOF - A subject of the present invention is mutated hyperthermophilic phosphotriesterases (PTEs) possessing a lactonase activity, and their uses as bioscavengers within the context of the decontamination of the surfaces of materials, of the skin or mucous membranes, contaminated with organophosphorus compounds, or within the context of the preparation of medicaments which can be used within the context of the prevention or treatment of an external contamination or of an internal poisoning by ingestion or inhalation by organophosphorus compounds, or within the context of the pollution control of water polluted with organophosphorus compounds.12-30-2010
20110010783METHOD FOR REPROGRAMMING IN VITRO STEM CELLS AND SOMATIC CELLS INTO GERMINAL CELLS - The present invention is related to a method for inducing in vitro the differentiation of stem cells or somatic cells towards germinal cells, comprising the following steps: 01-13-2011
20110010784INSULIN-LIKE GENE OF PRAWNS AND USES THEREOF - Nucleic acid molecules encoding an insulin-like factor of the androgenic gland of the freshwater prawn 01-13-2011
20110004951METHODS AND COMPOSITIONS FOR IDENTIFYING COMPOUNDS THAT INHIBIT HIV-1 SUBUNIT-SPECIFIC REVERSE TRANSCRIPTASE - This invention relates to methods and compositions for identifying compounds that inhibit HIV-1 subunit-specific reverse transcriptase.01-06-2011
20110041195Organisms homozygous for targeted modification - Disclosed herein are homozygously modified organisms and methods of making and using these organisms.02-17-2011
20110041194I-MSOI HOMING ENDONUCLEASE VARIANTS HAVING NOVEL SUBSTRATE SPECIFICITY AND USE THEREOF - An I-MsoI homing endonuclease variant able to cleave mutant I-MsoI sites having variation at positions ±8 to ±10, a vector encoding said variant, a cell, an animal or a plant modified by said vector. Use of said I-MsoI endonuclease variant and derived products for genetic engineering, genome therapy and antiviral therapy.02-17-2011
20110119777USE OF AAV REPLICATION MACHINERY FOR IMPROVED PROTEIN PRODUCTION - The present invention provides a method for enhanced production of a gene product of interest in a cell, using the AAV replication machinery. The present invention further relates to a cell for use in the method of the invention and a non-human transgenic animal or a transgenic plant comprising a cell of the invention.05-19-2011
20110119778STEGANOGRAPHIC EMBEDDING OF INFORMATION IN CODING GENES - The invention relates to the storage of information in nucleic acid sequences. The invention also relates to nucleic acid sequences containing desired information and to the design, production or use of sequences of this type.05-19-2011
20110247088TETRACYCLINE INDUCIBLE TRANSCRIPTION CONTROL SEQUENCE - The present invention relates to inducible transcription control sequences for the regulation of gene expression. Specifically, it relates to an transcription control sequence comprising at least two tet operator sequence motifs allowing the binding of tetracycline-dependent transcriptional regulators, wherein each of the said tetracycline-dependent transcriptional regulators binds with respect to its neighbour to an opposite face of the DNA helix, and a minimal promoter comprising a TATA box which is linked at its 5′ end to a general transcription factor binding site. Further, the present invention relates to a vector, a host cell, a plant or a non-human transgenic animal comprising the said transcription control sequence. Also contemplated is a method for regulating the expression of a nucleic acid sequence being operatively linked to the transcription control sequence of the present invention in a host cell, a plant or a non-human transgenic animal.10-06-2011
20110214192PHOTOCONVERTIBLE FLUORESCENT PROTEINS - The present disclosure provides an isolated nucleic acid sequence encoding a monomeric photoconvertible fluorescent protein, and fragments and derivatives thereof. Also provided is a method for engineering the nucleic acid sequence, a vector comprising the nucleic acid sequence, a host cell comprising the vector, and use of the vector in a method for expressing the nucleic acid sequence. The present disclosure further provides an isolated nucleic acid, or mimetic or complement thereof, that hybridizes under stringent conditions to the nucleic acid sequence. Additionally, the present provides a monomeric photoconvertible fluorescent protein encoded by the nucleic acid sequence, as well as derivatives, fragments, and homologues thereof. Also provided is an antibody that specifically binds to the photoconvertible fluorescent protein.09-01-2011
20100223682CASEIN AND METHODS OF USE THEREOF - This invention provides an altered kosher kappa casein polypeptide having at least one altered amino acid in a defined amino acid stretch. The defined amino acid stretch contributes to an allergic reaction induced by a kosher wild-type casein polypeptide in a human subject. Moreover, the defined amino acid stretch is expressed solely in kosher animals. The invention further provides an expression system for expressing the altered kosher casein polypeptide.09-02-2010
20100192239Modulation of Mu Delta Opioid Receptor Expression - In accordance with certain embodiments of the present disclosure, an expression cassette is provided. The expression cassette includes a heterologous nucleotide sequence that encodes a mu opioid receptor.07-29-2010
20100011454HUMAN ARTIFICIAL CHROMOSOME (HAC) VECTOR AND HUMAN CELL MEDICINE COMPRISING SAME - This invention relates to a human artificial chromosome (HAC) vector carrying a human chromosome-derived centromere, a subtelomere sequence, and a telomere sequence, to a human cell medicine or human cells comprising the HAC vector, to methods for preparing the HAC vector and human cells, and to methods for producing a therapeutic protein using the HAC vector.01-14-2010
20090222936Recombinant Expression of Multiprotein Complexes Using Polygenes - The present invention relates to a recombinant polynucleotide encoding a polygene coding for at least three polypeptides wherein at least one of the genes constituting the polygene is of non-viral origin, at least two of the polypeptides encoded by the genes constituting the polygene are each capable of at least transiently interacting with at least one other polypeptide encoded by a gene of said polygene, and the genes constituting the polygene are each connected to one mother by a sequence coding for at least one protease cleavage site. The present invention also relates to polyproteins encoded by the polygene. Further embodiments of the present invention are a vector containing the recombinant polypeptide, a host cell containing the recombinant polypeptide and/or the vector and a non-human transgenic animal transformed with the recombinant polypeptide and/or the vector. The present invention also relates to methods for the production of the polynucleotide and for the manufacture of multiprotein complexes. The embodiments of the present invention are particularly useful in gene therapy, drug candidate screening, vaccine production and crystallisation of multiprotein complexes for structural investigations.09-03-2009
20090313711NOVEL PROTEIN AND PRODUCTION PROCESS AND USE THEREOF - [PROBLEMS] To provide a polypeptide having a novel structure and showing an activity of inhibiting angiogenesis or an activity of inhibiting osteoclastogenesis, and to provide a recombinant protein by constructing a method of purifying the above protein. To provide an ingredient useful in designing remedies for tendinitis, rheumatoid arthritis, arthritis deformans, malignant tumor, etc.12-17-2009
20090217399Lentiviral Vectors That Provide Improved Expression And Reduced Variegation After Transgenesis - The present invention provides new lentiviral vectors that include an anti-repressor element (ARE) and, optionally, a scaffold attachment region (SAR). The lentiviral vectors provide expression of a heterologous nucleic acid in at least 50% of the cells of multiple cell types when used for lentiviral transgenesis. In certain embodiments of the invention the heterologous nucleic acid encodes an RNAi agent such as an shRNA. The invention further provides transgenic nonhuman animals generated using a lentiviral vector that includes an ARE and optional SAR. In addition, the invention provides a variety of methods for using the vectors including for achieving gene silencing in eukaryotic cells and transgenic animals, and methods of treating disease. The invention also provides animal models of human disease in which one or more genes is functionally silenced using a lentiviral vector of the invention.08-27-2009
20090217398METHODS TO IDENTIFY FAT AND LEAN ANIMALS USING CLASS PREDICTORS - A combination comprising two or more polynucleotides that are differentially expressed in fat animals compared to lean animals or two or more proteins produced by the expression of such polynucleotides is disclosed. The combination and probes based upon the combination are used for formulating a prognosis that an animal is likely to become fat, developing a diagnosis that an animal is fat, screening substances to determine if they are useful for modulating the amount of adipose tissue on an animal, and detecting the differential expression of one or more genes differentially expressed in fat animals compared to lean animals in a sample. Methods for using class predictor gene profiles to identify fat and lean animals are also disclosed.08-27-2009
20090217397Cre-lox based gene knockdown constructs and methods of use thereof - The present invention relates to vectors, compositions and methods for conditional, Cre-lox regulated, RNA interference. The vectors allow for spatial and temporal control of miRNA expression in vivo.08-27-2009
20090217396Inflammation models in neurodegenerative and arthritic disorders - Disclosed are compositions and methods for inducing temporally conditional mediators or inflammation and the transgenic animals produced by these compositions and method that can be used as models of inflammatory disease.08-27-2009
20100037329Development of sensitive fret sensors and methods of using the same - Intramolecular biosensors are disclosed, including PBP-based biosensors, comprising a ligand binding domain fused to donor and fluorescent moieties that permit detection and measurement of Fluorescence Resonance Energy Transfer upon binding ligand. At least one of the donor and fluorescent moieties may be internally fused to the biosensor such that both ends of the internally fused fluorophore are fixed. In addition, methods of improving the sensitivity of terminally fused biosensors are provided. The biosensors of the invention are useful for the detection and quantification of ligands in vivo and in culture.02-11-2010
20110093963Enhanced Expression of Human or Humanized Immunoglobulin in Non-Human Transgenic Animals - The present invention describes transgenic animals with human(ized) immunoglobulin loci and transgenes encoding human(ized) Igα and/or Igβ sequences. Of particular interest are animals with transgenic heavy and light chain immunoglobulin loci capable of producing a diversified human(ized) antibody repertoire that have their endogenous production of Ig and/or endogenous Igα and/or Igβ sequences suppressed. Simultaneous expression of human(ized) immunoglobulin and human(ized) Igα and/or Igβ results in normal B-cell development, affinity maturation and efficient expression of human(ized) antibodies.04-21-2011
20110252489METHOD OF IDENTIFYING PROLIFICACY IN MAMMALS - The present invention refers to a method of predicting prolificacy in mammals, by means of analyzing a specific molecular marker for a novel mutation correlated to the increase of the ovulation rate. The correct and simple identification of the presence of the mutation, provided by the use of the method can be highly useful in the genetic improvement of ewes, as well as flock reproduction management. The invention also refers to a novel mutation in the GDF-9 gene which positively alters the ovulation rate and to the use of said genetic sequence for the production of high prolificacy transgenic animals.10-13-2011
20110099647ANTIBODIES AGAINST CD38 FOR TREATMENT OF MULTIPLE MYELOMA - Isolated human monoclonal antibodies which bind to human CD38, and related antibody-based compositions and molecules, are disclosed. Also disclosed are pharmaceutical compositions comprising the human antibodies, and therapeutic and diagnostic methods for using the human antibodies.04-28-2011
20110093964URANIUM-CHELATING PEPTIDES AND USES THEREOF - The invention concerns uranium-chelating peptides as well as their uses for decontaminating soils and water, and for detecting and treating people contaminated by uranium. Said peptides have a helix-loop-helix type structure comprising the sequence of a calmodulin loop including at least one mutation of neutral residues selected from the group consisting of S, T, C, H, Y, N and Q, of one, two or three residues of at least one of the four calmodulin calcium binding sites: site I: residues selected among D20, D22 and D24 residues; site II: residues selected among D56, D58 and N60 residues; site III: residues selected among D93, D95 and N97 residues; site IV: residues selected among D129, D131 and D133 residues; said positions being indicated with reference to the human calmodulin sequence.04-21-2011
20110093962BREAST DISEASE TARGETS AND USES THEREOF - The present invention provides a method for diagnosing and detecting diseases associated with breast. The present invention provides one or more proteins or fragments thereof, peptides or nucleic acid molecules differentially expressed in breast diseases (BCAT) and antibodies binds to BCAT. The present invention provides that BCAT is used as targets for screening agents that modulates the BCAT activities. Further the present invention provides methods for treating diseases associated with breast.04-21-2011
20120304321USE OF MEGANUCLEASES FOR INDUCING HOMOLOGOUS RECOMBINATION EX VIVO AND IN TOTO IN VERTEBRATE SOMATIC TISSUES AND APPLICATION THEREOF - A monomer of an I-CreI meganuclease variant wherein said monomer when in dimeric form binds and cleaves DNA.11-29-2012
20120304320TRANSGENIC BIOSENSORS - Systems and methods relate to transgenic organisms and their use as biosensors are described. In some embodiments, the systems and methods include a first population of transgenic organisms that includes a first constitutively expressed reporter gene, and a first transgene that includes a first inducible promoter from a response pathway gene, wherein the first inducible promoter is coupled to a first reporter gene. Other embodiments are described.11-29-2012
20110078805COMPOSITIONS AND METHODS FOR GENERATING TRANSGENIC ANIMALS - The present invention provides methods of altering gene expression of embryos to provide compositions and methods for efficient generation of transgenic animals. In particular, the present invention provides compositions and methods for generating germ-line transgenic animals by direct injection of nucleic acid molecules into animals.03-31-2011
20110088105DEVELOPMENT STAGE-SPECIFIC LETHALITY SYSTEM FOR INSECT POPULATION CONTROL - The application describes a transgenic insect comprising a developmental stage-specific lethality system. The developmental stage-specific lethality system comprises a first gene expression cassette comprising a first promoter/enhancer element of a developmental stage-specific gene derived from an insect pest species, preferably from a member of the family Tephritidae, a first component of a transactivating system, a second gene expression cassette comprising a second component of the transactivating system, a second promoter responsive to the activity of the transactivating system, and a lethality inducing system. Also, the application describes a method of controlling reproduction in an insect population of interest, comprising providing a plurality of insects according to the invention and allowing the insects to interbreed with insects of the population of interest. Further, the application describes a method for producing transgenic insects comprising a developmental stage-specific lethality system comprising providing a set of insects comprising gene expression cassettes according to the invention, and further evaluating the insects or offspring thereof for functionality of the developmental stage-specific lethality system. Also, the application describes the use of a transgenic insect according to the invention for controlling reproduction in an insect population of interest. Further, the application describes a developmental stage-specific lethality system for use in a transgenic insect comprising gene expression cassettes according to the invention.04-14-2011
20100125919METHODS AND COMPOSITIONS FOR MODULATING THE MIRNA PATHWAY - A specific spectrum of plant and animal miRNAs confer enhanced resistance to virulent pathogens. Plants deficient in miRNA accumulation are hyper-susceptible to non-virulent bacterial pathogens, and virulent bacteria suppress miRNA pathways by means of injected type-III secreted (TTS) proteins. Methods and compositions for modulating the miRNA pathway in plants and animals are disclosed whereby adverse effects on plant and animal development are avoided or minimized.05-20-2010
20110252488Method of Identifying Genes which Promote Hybrid Vigour and Hybrid Debility and Uses Thereof - The invention relates to a method of identifying candidate genes that are potentially useful in the diagnosis and treatment of disease and/or inducement of hybrid vigour. In particular, the present invention relates to a method for identifying candidate genes capable of producing hybrid vigour or hybrid debility in an animal or plant, comprising the steps of: (i) comparing the nucleotide sequence of alleles of candidate genes; (ii) identifying nucleotide sequence differences in the alleles from said animal or plant; and (iii) identifying that the amino acid sequence variation between alleles of the candidate gene are located within two or more different exons within the candidate gene.10-13-2011
20110061118VECTORS AND METHODS FOR GENERATING VECTOR-FREE INDUCED PLURIPOTENT STEM (IPS) CELLS USING SITE-SPECIFIC RECOMBINATION - The present invention relates to a DNA molecule comprising: (a) a first DNA sequence comprising: (aa) a coding sequence giving rise upon transcription to a factor that contributes to the reprogramming of a somatic cell into an induced pluripotent stem (iPS) cell; (ab) a promoter mediating the transcription of said coding sequence; and (ac) two sequence motifs that mediate excision of (aa) and/or (ab) from the DNA molecule, wherein one sequence motif is positioned 5′ and the other sequence motif is positioned 3′ of the sequence to be excised; (b) a second DNA sequence comprising a sequence motif that mediates site-specific integration of (a) into another DNA molecule. Further, the invention relates to DNA molecule comprising: (a) a first DNA sequence comprising: (aa) a coding sequence giving rise upon transcription to a factor that contributes to the reprogramming of a somatic cell into an induced pluripotent stem cell; and (ab) a promoter mediating the transcription of said coding sequence; (b) a second DNA sequence comprising: (ba) a sequence motif that mediates extrachromosomal self-replication of the DNA-molecule; and (bb) two sequence motifs that mediate excision of at least said sequence motif of (ba) from the second DNA sequence (b), wherein one sequence motif is located 5′ of (ba) and the other sequence motif 3′ of (ba). Also, the invention relates to a vector comprising the DNA molecule of the invention, a method for assembly of said vector and a somatic cell comprising said DNA molecule or said vector of the invention. Furthermore, the invention relates to methods to generate an induced pluripotent stem (iPS) cell, an induced pluripotent stem cell obtainable by said methods, to a kit comprising the DNA molecule of the invention, to a cell line or cell culture collection comprising the induced pluripotent stem cell of the invention, to the use of said cell or cell line as a research tool, to a method to generate a transgenic non-human animal and to a non-human animal generated by said method. Finally, the invention relates to a composition for gene therapy, regenerative medicine, cell therapy or drug screening.03-10-2011
20110030075Methods and Compositions Capable of Causing Post-Transcriptional Silencing of Gene Expression in a Synergic Manner - The invention relates to compositions for the post-transcriptional inhibition of gene expression by means of the combined use of a modified U1 snRNA targeted at a pre-selected region in a target pre-mRNA and of a gene expression-silencing agent of the siRNA, shRNA and/or miRNA type, as well as the use of said combinations for the treatment of diseases caused by the unwanted over-expression of a protein.02-03-2011
20110258714PHYTASE VARIANTS - The present invention relates to a phytase which has at least 74% identity to a phytase derived from 10-20-2011
20100325744NON-GLYCOSYLATED RECOMBINANT MONOVALENT ANTIBODIES - The present invention provides non-glycosylated monovalent antibodies with a long half-life when administered in vivo, methods of making such monovalent antibodies, pharmaceutical compositions comprising such antibodies, and uses of the monovalent antibodies.12-23-2010
20130160152Hyperactive Piggybac Transposases - The present invention provides PiggyBac transposase proteins, nucleic acids encoding the same, compositions comprising the same, kits comprising the same, non-human transgenic animals comprising the same, and methods of using the same.06-20-2013
20110154519HAFNIA PHYTASE - The present invention relates to isolated polypeptides having phytase activity and isolated polynucleotides encoding the polypeptides. The polypeptides are related to a phytase derived from Hafnia alvei, the amino acid sequence of which is shown in the appended sequence listing as SEQ ID NO: 10. The invention also relates to nucleic acid constructs, vectors, and host cells comprising the polynucleotides as well as methods for producing and using the polypeptides, in particular within animal feed.06-23-2011
20110154517DISORDERS OF VASOREGULATION AND METHODS OF DIAGNOSING THEM - The present invention relates to various in vitro methods of diagnosing a vasoregulation disorder or a predisposition thereto in a subject being suspected of having developed or of having a predisposition to develop a vasoregulation disorder or in a subject being suspected of being a carrier for a vasoregulation disorder, wherein the vasoregulation disorder is selected from hypertension, migraine, pre-eclampsia and recurrent pregnancy loss. Moreover, the present invention also relates to methods for identifying compounds capable of modulating coagulation factor XII activity, suitable as medicaments or as lead compound for a medicament for the treatment and/or prevention of a vasoregulation disorder. Furthermore, the present invention relates to gene therapy methods and to a kit for diagnosing a vasoregulation disorder.06-23-2011
20100122361HUMANISATION OF ANIMALS - The present invention relates to the generation of transgenic animal cells and/or animals in which a large portion of a host animal's genome has been replaced with an equivalent syntenic portion of nucleic acid from the genome of a different organism.05-13-2010
20100281551MODIFIED TRANSPOSON VECTOR AND ITS USE - A modified transposon vector and a method for introducing a foreign gene into a cell are provided. A modified transposon vector wherein a nucleic acid fragment having the following features (a)-(b) or (a)-(c) is inserted; a cell expressing a foreign gene obtained by introducing said vector into chromosomal DNA of a cell line or an ontogenetic cell and further introducing an expression cassette of a foreign gene into the chromosomal DNA; a genetically recombined animal generated by using said cell (in case of an ontogenetic cell); and a method for producing a foreign protein from said cell and said genetically recombined animal: 11-04-2010
20100100977PROBE FOR VISUALIZING CELL-CYCLE - An object of an embodiment of the present invention is to provide a method with which it is possible to easily distinguish a proliferation phase of a cell cycle from a resting phase thereof in real time. The object of the embodiment of the present invention is attained by providing a method for performing phase identification of the cell cycle, the method including: visualizing one or more gene-expression products as markers whose amounts in a cell change in a cell-cycle dependent manner; and detecting the products so as to distinguish the proliferation phase of the cell cycle from the resting phase thereof.04-22-2010
20100083392HAFNIA PHYTASE VARIANTS - The present invention relates to phytases having at least 76% identity to a phytase derived from 04-01-2010
20100058489Nucleic Acid Encoding A Brain Derived Tau Kinase Polypeptide and Methods of Use Thereof - The present invention provides materials and methods for treating Alzheimer's disease and other tau related neurodegenerative disorders. A tau kinase, Brain Derived Tau Kinase (BDTK) is provided. BDTK can cause hyperphosphorylation of tau protein, which leads to formation of neurofibrillary tangles, which are implicated in the degenerative symptoms of Alzheimer's and other neurodegenerative disorders. Methods of diagnosis and treatment based on the discovery of this novel tau kinase are also provided.03-04-2010
20120204277Non-Aggregating Fluorescent Proteins and Methods for Using the Same - Nucleic acid compositions encoding non-aggregating chromo/fluoroproteins and mutants thereof, as well as the proteins encoded by the same, are provided. The proteins of interest are polypeptides that are non-aggregating colored and/or fluorescent proteins, where the non-aggregating feature arises from the modulation of residues in the N-terminus of the protein and the chromo and/or fluorescent feature arises from the interaction of two or more residues of the protein. Also provided are fragments of the subject nucleic acids and the peptides encoded thereby, as well as antibodies to the subject proteins and transgenic cells and organisms. The subject protein and nucleic acid compositions find use in a variety of different applications. Finally, kits for use in such applications, e.g., that include the subject nucleic acid compositions, are provided.08-09-2012
20080229437Intergeneric bivalve shellfish hybrid and method for producing - Provided by this invention are novel intergeneric bivalve shellfish hybrids, including clams and scallops. Also provided are methods for producing the novel hybrids and their progeny.09-18-2008
20080216184MUTANT RECEPTORS AND THEIR USE IN A NUCLEAR RECEPTOR-BASED INDUCIBLE GENE EXPRESSION SYSTEM - This invention relates to the field of biotechnology or genetic engineering. Specifically, this invention relates to the field of gene expression. More specifically, this invention relates to novel substitution mutant receptors and their use in a nuclear receptor-based inducible gene expression system and methods of modulating the expression of a gene in a host cell for applications such as gene therapy, large scale production of proteins and antibodies, cell-based high throughput screening assays, functional genomics and regulation of traits in transgenic organisms.09-04-2008
20100325745MEGANUCLEASE VARIANTS CLEAVING A DNA TARGET SEQUENCE FROM THE MOUSE ROSA26 LOCUS AND USES THEREOF - An I-CreI variant, wherein one of the two I-CreI monomers has at least two substitutions, one in each of the two functional subdomains of the LAGLIDADG (SEQ ID NO: 150) core domain situated respectively from positions 26 to 40 and 44 to 77 of I-CreI, said variant being able to cleave a DNA target sequence from the mouse ROSA26 locus. Use of said variant and derived products for the engineering of transgenic mice and recombinant mouse cell lines expressing an heterologous protein of interest.12-23-2010
20080250514Expression Systems Using Mammalian Beta-Actin Promoter - Promoter activities were examined by comparing combinations of promoters and enhancers derived from various genes. A hybrid promoter comprising a combination of a CMV enhancer and a mammalian β-actin promoter, or the post-transcriptional regulatory region of the genomic sequence Woodchuck Hepatitis Virus (WPRE) and a mammalian β-actin promoter was found to be stronger than existing promoters. Furthermore, the activities of the β-actin promoters could be enhanced by coexpressing the oncogene product Ras, which is a transactivator.10-09-2008
20110126303Modified Blood Clotting Factors And Methods Of Use - The invention provides compositions including modified blood clotting factors that have a non-native proteolytic cleavage site engineered into them allowing intracellular cleavage and secretion of an active form. The compositions are useful in the methods for treating a bleeding or clotting disorder.05-26-2011
20110126302DIAGNOSTIC AND THERAPEUTIC METHODS FOR EFMR (EPILEPSY AND MENTAL RETARDATION LIMITED TO FEMALES) - Methods and kits for the diagnosis of illnesses related to protocadherin 19 (PCDH 19) protein deficiency or altered PCDH 19 protein function, in particular EFMR (Epilepsy and Mental Retardation limited to Females) are provided, as well as methods and kits for the identification of a predisposition to such illnesses and methods of screening subjects to identify carriers of such illnesses and methods and kits for the therapeutic or prophylactic treatment of PCDH 19 deficiency or altered PCDH 19 protein function. Further, nucleotide and amino acid sequences corresponding to a complete PCDH19 open reading frame (ORF), mutant sequences encoding non-functional PCDH19 mRNA or altered PCDH19 mRN A are described along with transformed cells and non-human transgenic animals comprising wild-type or mutant PCDH19 ORF nucleotide sequences.05-26-2011
20110126301Dendritic Cell Marker and Uses Thereof - The present invention relates to the identification of proteins located on the cell surface of dendritic cells or precursors thereof, particularly antigen presenting dendritic cells. In particular, the present invention relates to compounds such as antibodies that bind these proteins. These compounds can be used to detect and/or enrich a subset of dendritic cells or precursors thereof. These compounds can also be used to target antigens to dendritic cells or precursors thereof to modulate a humoral and/or T cell mediated immune response to an antigen, or used to target cytotoxic agents to dendritic cells or precursors thereof involved in diseased states.05-26-2011
20110138490DESATURASE AND METHOD FOR THE PRODUCTION OF POLYUNSATURATED FATTY ACIDS IN TRANSGENIC ORGANISMS - The present invention relates to a polynucleotide from 06-09-2011
20110191873Methods of Protein Destabilization and Uses Thereof - This invention is directed towards methods of destabilizing proteins in living cells, and their use for the development of novel assays. In one embodiment, the invention comprises the use of non-cleavable multimerized ubiquitin fusion proteins to destabilize a target protein, such as a reporter moiety. In one aspect of this method the constructs also comprises a linker that operatively couples the reporter moiety to the multimerized ubiquitin fusion protein. In this embodiment, enzymatic modification of the linker results in a modulation of the coupling of the reporter protein to the multimerized ubiquitin domains resulting in a change in the stability of the reporter moiety. The level of the reporter moiety in the cell can then be used as a measure of the enzymatic activity in the cell. In another embodiment the invention provides for a generalized way of coordinately regulating the cellular concentration of a plurality of target proteins. In one aspect of this method, the target proteins are operatively coupled to a ubiquitin fusion protein via a linker containing a protease cleavage site. Cleavage of the linker by a protease results in uncoupling of the target protein from the multimerized ubiquitin construct, and results in an increase in the stability and concentration of the target protein.08-04-2011
20110191871METHODS TO IDENTIFY FACTORS ASSOCIATED WITH MUSCLE GROWTH AND USES THEREOF - The present invention relates to methods to identify factors associated with muscle growth, angiogenesis, obesity, insulin sensitivity body weight, fat mass, muscle mass and cardiovascular function. In particular, the methods of the present invention relates to assays to identify such factors using a transgenic animal model and/or a cell-based assay.08-04-2011
20110088104NOVEL ANTIBODIES FOR THE TREATMENT OF HIV - The present invention relates to novel isolated antibodies, or the derivatives or antigen binding fragments of same, capable of binding to CXCR4 but also of inducing conformational changed of the CXCR4 homodimers and able to inhibit HIV-1 primary isolate replication in PBMC.04-14-2011
20110154518GENERATION OF INDUCED PLURIPOTENT STEM (iPS) CELLS - The present invention relates to a method of generating an induced pluripotent stem (iPS) cell comprising the step of introducing into a target cell one or two coding sequences each giving rise upon transcription to a factor that contributes to the reprogramming of said target cell into an induced pluripotent stem cell and selected from Oct3/4 or a factor belonging to the Myc, Klf and Sox families of factors, wherein the target cell endogenously expresses at least the factors that are not encoded by the coding sequences to be introduced and selected from Oct3/4 or factors belonging to the Myc, Klf and Sox families of factors, and wherein the cell resulting from the introduction of the one or two coding sequences expresses the combination of factor Oct3/4 and at least one factor of each family of factors selected from the group of Myc, Klf and Sox. Furthermore, the present invention relates to an induced pluripotent stem cell generated by the method of the invention and a method of identifying a compound that contributes to the reprogramming of a target cell into an induced pluripotent stem cell. Also, a method of generating a transgenic non-human animal and a composition comprising an iPS cell generated by the method of the present invention for gene therapy, regenerative medicine, cell therapy or drug screening are envisaged.06-23-2011
20110154516HUMAN FACTOR IX VARIANTS WITH AN EXTENDED HALF LIFE - Factor IX variants are described with an increase in the number of glycosylation sites. The Factor IX variants have an increased half life and/or recovery.06-23-2011
20110154515GENETICALLY ENCODED CALCIUM SENSORS COMPRISING THE C-TERMINAL LOBE OF TROPONIN C AND A FLUORESCENCE TAG - The present invention relates to genetically encoded calcium sensors comprising fluorescent proteins and troponin C as calcium-binding moiety. More specifically, the invention provides a polypeptide comprising a donor moiety for fluorescence resonance energy transfer (FRET), at least two calcium binding moieties derived from the C-terminal domain of troponin C, and an acceptor moiety for FRET. Also, the invention provides nucleic acid molecules, expression vectors, host cells, and transgenic animals. In addition, methods for detecting a change in Ca06-23-2011
20110265195UNIQUE ASSOCIATED KAPOSI'S SARCOMA VIRUS SEQUENCES AND USES THEREOF - This invention provides an isolated peptide encoded by a nucleic acid which is at least 30 nucleotides in length and has a sequence which uniquely defines a herpesvirus associated with Kaposis' sarcoma, which herpesvirus is present in and recoverable from the HBL-6 cell line (ATCC Accession No. CRL 11762).10-27-2011
20100017901Compositions Comprising MG29 Nucleic Acids, Polypeptides, and Associated Methods of Use - Disclosed herein are compositions and methods for treatment of muscle dysfunction (including sarcopenia) and other diseases involving skeletal muscle, including age-related muscle dysfunction. In addition, the invention relates to therapeutic compositions comprising nucleotides and/or polypeptides of the invention in combination with a pharmaceutically acceptable carrier, wherein the composition facilitates the treatment of skeletal muscle disorder, including those related to thr normal aging process. Moreover, the invention relates to the treatment and/or prevention of pathological conditions associated with altered intracellular Ca2+ regulation and disrupted membrane structure that occurs when the expression levels of MG29 are reduced.01-21-2010
20080289056CHEMOENZYMATIC METHODS FOR THE SYNTHESIS OF STATINS AND STATIN INTERMEDIATES - The invention provides aldolases, nucleic acids encoding them and methods for making and using them, including chemoenzymatic processes for making β,δ-dihydroxyheptanoic acid side chains and compositions comprising these side chains, e.g., [R—(R*,R*)]-2-(4-fluorophenyl)-b,d-dihydroxy-5-(1-methylethyl)-3-phenyl-4-(phenylamino)-carbonyl]-1H-pyrrole-1-heptanoic acid (atorvastatin, LIPITOR™), rosuvastatin (CRESTOR™), fluvastatin (LESCOL™), related compounds and their intermediates.11-20-2008
20100287633Hyperactive PiggyBac Transposases - The present invention provides PiggyBac transposase proteins, nucleic acids encoding the same, compositions comprising the same, kits comprising the same, non-human transgenic animals comprising the same, and methods of using the same.11-11-2010
20090300781PREDICTION OF HETEROSIS AND OTHER TRAITS BY TRANSCRIPTOME ANALYSIS - Transcriptome-based prediction of heterosis or hybrid vigour and other complex phenotypic traits. Analysis of transcript abundance in predictive gene sets, for predicting magnitude of heterosis or other complex traits in plants and animals. Transcriptome-based screening and selection of individuals with desired traits and/or good hybrid vigour.12-03-2009
20120042399IMMUNOGENIC PEPTIDES - The present invention relates to immunogenic peptides and their various applications. In particular the invention relates to immunogenic peptides derived from the PASD1 protein and their use in therapeutic, diagnostic and prognostic methods.02-16-2012
20090083870Systems for gene targeting and producing stable genomic transgene insertions - The novel germ-line transformation systems disclosed in this patent application allow the physical deletion of transposon DNA following the transformation process, and the targeting of transgene integrations into predefined target sites. In this way, transposase-mediated mobilization of genes-of-interest is excluded mechanistically and random genomic integrations eliminated. In contrast to conventional germ-line transformation technology, our systems provide enhanced stability to the transgene insertion. Furthermore, DNA sequences required for the transgene modification (e.g. transformation marker genes, transposase or recombinase target sites), are largely removed from the genome after the final transgene insertion, thereby eliminating the possibility for instability generated by these processes. The RMCE technology, which is disclosed in this patent application for invertebrate organisms (exemplified in 03-26-2009
20120047588Methods for Conditional and Inducible Transgene Expression to Direct the Development of Embryonic, Embryonic Stem, Precursor and Induced Pluripotent Stem Cells - Methods are disclosed in which the expression of a specific gene, or combinations of genes, is controlled spatially and temporally to develop intra- and interspecies chimeras. A transgenic EC/ES/P/iPS cell line is created which conditionally expresses a suicide or compromiser gene configured to compromise all cell lineages except that corresponding to a target tissue/organ. The EC/ES/P/iPS cell line is injected into donor embryos having a specific target gene deficiency or embryos genetically engineered to be complementary compromised in lineages corresponding to the target tissue/organ cell lineages of the EC/ES/P/iPS line. One or more stimuli is provided to the embryo to activate compromiser genes for ablation of non-target tissues/organs of the EC/ES/P/iPS line and target tissues/organs of the host embryo, resulting in a chimeric animal having target tissues/organs derived from the genotype of the transgenic cell line and all remaining tissues/organs derived from the donor embryo.02-23-2012
20120005767ANTIBODIES TO INSULIN-LIKE GROWTH FACTOR I RECEPTOR - The present invention relates to antibodies and antigen-binding portions thereof that specifically bind to insulin-like growth factor I receptor (IGF-IR), which is preferably human IGF-IR. The invention also relates to human anti-IGF-IR antibodies, including chimeric, bispecific, derivatized, single chain antibodies or portions of fusion proteins. The invention also relates to isolated heavy and light chain immunoglobulin molecules derived from anti-IGF-IR antibodies and nucleic acid molecules encoding such molecules. The present invention also relates to methods of making anti-IGF-IR antibodies, pharmaceutical compositions comprising these antibodies and methods of using the antibodies and compositions thereof for diagnosis and treatment. The invention also provides gene therapy methods using nucleic acid molecules encoding the heavy and/or light immunoglobulin molecules that comprise the human anti-IGF-IR antibodies. The invention also relates to gene therapy methods and transgenic animals comprising nucleic acid molecules of the present invention.01-05-2012
20120011597CERTAIN HUMAN GENOMIC DNA ASSOCIATED WITH TOTAL RED-GREEN COLORBLINDNESS - Disclosed is human genomic DNA having the following STR marker profile:01-12-2012
20090044286Estrogen receptor intramolecular folding systems, estrogen receptor intramolecular folding sensors, methods of use thereof, methods of detecting ER ligands, and methods of detecting ER agonists and antagonists - Briefly described, embodiments of this disclosure include estrogen receptor (ER) intramolecular folding systems, methods of detecting ER ligands and distinguishing between ER agonists and antagonists, cells including ER intramolecular folding systems, transgenic animals including ER intramolecular folding systems, fusion proteins, and the like.02-12-2009
20120023600COMPOSITIONS AND METHODS OF USE FOR ANTIBODIES OF DICKKOPF-1 - Antibodies and fragments that bind to the protein target Dickkopf (DKK1) are provided, as are methods of use and kits, for treating a target cell, in particular, a cell associated with an osteolytic condition.01-26-2012
20120159659CUSTOM-MADE MEGANUCLEASE AND USE THEREOF - New rare-cutting endonucleases, also called custom-made meganucleases, which recognize and cleave a specific nucleotide sequence, derived polynucleotide sequences, recombinant vector cell, animal, or plant comprising said polynucleotide sequences, process for producing said rare-cutting endonucleases and any use thereof, more particularly, for genetic engineering, antiviral therapy and gene therapy.06-21-2012
20120124684COMPOSITIONS AND METHODS USING ALPHA BETA-CRYSTALLIN IN PROTECTING THE MYOCARDIUM FROM ISCHEMIA/REPERFUSION INJURY - The invention provides a modified version of alpha B-Crystallin (αBC), and methods for delivering this modified version of alpha B-Crystallin (αBC) to tissues and cells; the invention provides a modified version of αBC in which the serine at position 59 has been changed to glutamate to mimic phosphorylation and the serine at positions 19 and 45 have been changed to alanine to prevent phosphorylation of those residues. The invention also provides compositions and methods for ameliorating a cell from ischemia/reperfusion injury or protecting a cell from ischemia/reperfusion injury.05-17-2012
20120124683Delivery method - The present invention relates, in general, to siRNA and, in particular, to a method of effecting targeted delivery of siRNAs and to compounds suitable for use in such a method.05-17-2012
20110107443NOVEL PROTEIN TRANSDUCTION DOMAINS DERIVED FROM SECRETORY LEUKOCYTE PROTEASE INHIBITOR - This invention relates to novel protein transduction domains (PTDs) derived from secretory leukocyte protease inhibitor (SLPI). SLPI-derived PTDs are able to deliver cargo moieties in vivo and in vitro into the cytoplasm and nucleus of a host cell. The invention also relates to a transduction complex comprising one or more SLPI-derived PTDs linked or fused to one or more cargo moieties, which may comprise, for example, proteins, nucleic acids, lipids, carbohydrates, small molecules and other chemical compounds. The invention also relates to the manufacture of SLPI-derived PTDs, complexes comprising them; compositions comprising SLPI-derived PTDs or complexes; and utilization of SLPI-derived PTDs or complexes comprising them for therapeutic, diagnostic and research methods involving delivery of heterologous molecules across cellular membranes, and especially, across nuclear membranes.05-05-2011
20100095391REGULATION OF LIPID DROPLET FORMATION BY MODULATION OF FIT1 AND FIT2 AND USES THEREOF - This invention provides methods of regulating fat storage in tissue by modulating the levels of Fibrate Induced Transcript 1 (FIT1) and/or Fibrate Induced Transcript 2 (FIT2), as well as diagnostic screens for disorders and conditions involving regulation of fat storage in tissue, assays for identifying agents that can regulate fat storage in tissue through modulating the levels of FIT1 and/or FIT2, and genetically altered mammals in which expression of FIT1 and/or FIT2 is altered in one or more tissue.04-15-2010
20100095390Aldolases, Nucleic Acids Encoding Them and Methods for Making and Using Them - This invention relates to polypeptides having aldolase activity, including pyruvate activity such as, without limitation, HMG and/or KHG aldolase activity, polynucleotides encoding these polypeptides, and methods of making and using these polynucleotides and polypeptides. In some embodiments, the invention is directed to polypeptides having aldolase activity, including pyruvate activity such as, without limitation, HMG and/or KHG aldolase activity, including thermostable and thermotolerant activity, and polynucleotides encoding these enzymes, and making and using these polynucleotides and polypeptides. The polypeptides in accordance with the invention can be used in a variety of pharmaceutical, agricultural and industrial contexts. In some embodiments, the invention provides polypeptides and biosynthetic pathways that are useful in the production of R-2-hydroxy 2-(indol-3ylmethyl)-4-keto glutaric acid (R-MP) and certain stereoisomers of monatin, such as R,R and S,R monatin, and salts thereof, as well as certain stereoisomers of monatin derivatives, such as the R,R and S,R configurations, and salts thereof.04-15-2010
20110099646GREEN FLUORESCENT PROTEIN OPTIMIZED FOR EXPRESSION WITH SELF-CLEAVING POLYPEPTIDES - The present invention provides a new fluorescent protein, engineered to facilitate release from self-cleaving peptides.04-28-2011
20120317664USE OF MEGANUCLEASES FOR INDUCING HOMOLOGOUS RECOMBINATION EX VIVO AND IN TOTO IN VERTEBRATE SOMATIC TISSUES AND APPLICATION THEREOF - A monomer of an I-CreI meganuclease variant wherein said monomer when in dimeric form binds and cleaves DNA.12-13-2012
20100235934HYDROCARBON-PRODUCING GENES AND METHODS OF THEIR USE - The invention provides isolated nucleic acids and isolated polypeptides involved in the synthesis of hydrocarbons and hydrocarbon intermediates. Homologs of, conservative variants of, and sequences having at least about 35% sequence identity with nucleic acids involved in the synthesis of hydrocarbons and hydrocarbon intermediates are also provided. The invention further provides methods for producing an aliphatic ketone or a hydrocarbon, as well as a method for identifying an enzyme useful for the production of hydrocarbons.09-16-2010
20100287632Rapid Production of Monoclonal Antibodies - The present invention relates to genetically altered hybridomas, myelomas and B cells. The invention also relates to utilizing genetically altered hybridomas, myelomas and B cells in methods of making monoclonal antibodies. The present invention also provides populations of hybridomas and B cells that can be utilized to make a monoclonal antibody of interest.11-11-2010
20100299769NOVEL PEPTIDE INVOLVED IN ENERGY HOMEOSTASIS - The expression of a mRNA encoding a putative 76 amino acid, secreted protein (“Enho1”) was found to negatively correlate with fasting triglyceride and cholesterol levels. A recombinant adenovirus was used to increase the expression of Enho1 mRNA in two mouse models of obesity, KK-A11-25-2010
20110191872METHOD FOR THE HUMANIZATION OF ANTIBODIES AND HUMANIZED ANTIBODIES THEREBY OBTAINED - Method for the humanization of the VH and VL variable regions of an animal antibody of known sequence, humanized animal antibody obtainable according to the method, in particular anti-NGF and anti-TrkA humanized animal antibodies.08-04-2011
20100275282METHODS AND SYSTEMS FOR IDENTIFYING IMMUNOMODULATORY SUBSTANCES - A method and system is presented for screening bacteria, products purified or made by bacteria and/or other bacterial substance for anti-inflammatory ability.10-28-2010
20100275279Selecting animals for parentally imprinted traits - Described are methods for selecting a domestic animal having desired genotypic properties, the methods comprising testing the animal for the presence of a parentally imprinted quantitative trait locus (QTL). The invention further relates to the use of an isolated and/or recombinant nucleic acid comprising a QTL or functional fragment derived therefrom to select a breeding animal or animal destined for slaughter having desired genotypic or potential phenotypic properties. In particular, the properties are related to muscle mass, fat deposition, sow prolificacy, and/or sow longevity.10-28-2010
20120260356MEGANUCLEASE VARIANTS CLEAVING AT LEAST ONE TARGET IN THE GENOME OF A RETROVIRUS AND USES THEREOF - Meganuclease variants which cleave at least one target in the provirus of a retrovirus and in particular which cleave the genomic insertion of the provirus. The present invention in particular relates to meganuclease variants which cleave the provirus of the Human Immunodeficiency Virus genome following genomic insertion. Vector encoding such variants, as well as to a cell or multi-cellular organism modified by such a vector and use of said meganuclease variants and derived products for genome engineering and for in vivo and ex vivo (gene cell therapy) genome therapy.10-11-2012
20080301825NOVEL SUBSTITUTION MUTANT RECEPTORS AND THEIR USE IN A NUCLEAR RECEPTOR-BASED INDUCIBLE GENE EXPRESSION SYSTEM - This invention relates to the field of biotechnology or genetic engineering. Specifically, this invention relates to the field of gene expression. More specifically, this invention relates to novel substitution mutant receptors and their use in a Group H nuclear receptor-based inducible gene expression system and methods of modulating the expression of a gene in a host cell for applications such as gene therapy, large scale production of proteins and antibodies, cell-based high throughput screening assays, functional genomics and regulation of traits in transgenic organisms.12-04-2008
20080301826NOVEL BETA-ACTIN AND RPS21 PROMOTERS AND USES THEREOF - The invention relates to isolation of novel β-actin and ribosomal protein S21 (rpS21) promoters and uses thereof. In particular, this invention features nucleotide sequences for rodent β-actin promoters including, hamster, rat, and mouse, and hamster rpS21 promoter.12-04-2008
20110004952METHOD FOR THE SEPARATION OF CELLS - The invention relates to a cell containing a gene encoding a conditional transgenic surface marker that is detectable upon expression on the surface of the cell, wherein the gene encoding a conditional transgenic surface marker comprises: (i) a promoter, operably linked to (ii) a first transcription sequence, and (iii) a second transcription sequence encoding the surface marker, whereby the first transcription sequence prevents the transcription of the second transcription sequence, whereby the first transcription sequence is conditionally removable such that the second transcription sequence is transcribable, and whereby the surface marker renders the cell sortable through the detection of the conditional transgenic surface marker. Furthermore, the invention relates to a construct for generating such a cell, and to a method for separating such a cell from a population of cells.01-06-2011
20110131670Non-Aggregating Fluorescent Proteins and Methods for Using the Same - Nucleic acid compositions encoding non-aggregating chromo/fluoroproteins and mutants thereof, as well as the proteins encoded by the same, are provided. The proteins of interest are polypeptides that are non-aggregating colored and/or fluorescent proteins, where the non-aggregating feature arises from the modulation of residues in the N-terminus of the protein and the chromo and/or fluorescent feature arises from the interaction of two or more residues of the protein. Also provided are fragments of the subject nucleic acids and the peptides encoded thereby, as well as antibodies to the subject proteins and transgenic cells and organisms. The subject protein and nucleic acid compositions find use in a variety of different applications. Finally, kits for use in such applications, e.g., that include the subject nucleic acid compositions, are provided.06-02-2011
20100175141TUNABLE GENETIC SWITCH FOR REGULATING GENE EXPRESSION - The present invention relates generally the field of genetics, in particular methods, compositions and systems for controlling the inducible expression of transgenes, while eliminating background expression of transgene expression. The present invention relates to methods of use of the compositions and systems as disclosed herein for controlling the inducible expression of transgenes while eliminating background expression of transgene expression, such as use in, for example, the in generation of transgenic animals, use in therapeutic application and use in assays. In some embodiments, the present invention relates to a system of controlled expression of RNAi molecules which target binding sites in the untranslated regions of transgene, thereby the expression of the transgene is modulated and leakiness is reduced. The compositions and methods of the present invention can be used to for therapy, prophylaxis, research and diagnostics in diseases and disorders which afflict mammalian species, generation of transgenic animals, in the study of biological processes as well as for enhance performance of agricultural crops.07-08-2010
20120240246Variant Calpastatins and Variant Calpains for Modulating the Activity or Stability of Calpain - The present invention features stabilized/destabilized variant calpastatin proteins and peptides that modulate the stability/activity of calpain for use in analyzing the pathophysiology of diseases associated with calpain activity, facilitating muscle growth and in improving meat tenderization.09-20-2012
20120266264MONOCLONAL ANTIBODIES AGAINST GONADOTROPIN-RELEASING HORMONE RECEPTOR - Monoclonal antibodies against gonadotropin releasing hormone (GnRH) receptor induce cellular apoptosis of various cancer cells expressing this surface receptor. The monoclonal antibodies and their humanized forms, or fragments thereof, can serve as anti-cancer agents for the treatment of cancer in humans, and can function as analogs of GnRH to affect regulation of reproductive functions or fertility in humans.10-18-2012
20110047634METHODS AND COMPOSITIONS FOR THE DIAGNOSIS AND TREATMENT OF ACUTE LYMPHOBLASTIC LEUKEMIA - Compositions and methods for the identification, prognosis, classification, diagnosis, and treatment of leukemia or a genetic predisposition to leukemia are provided. The present invention is based on the discovery of a novel intragenic deletion in the v-ets erythroblastosis virus E26 oncogene homolog (ERG) allele which is shown herein to be associated with a novel subtype of B-progenitor acute lymphoblastic leukemia (ALL). In one embodiment, the intragenic deletion in ERG results in the expression of C-terminal domain deletion forms of the ERG polypeptide which lacks the DNA-binding PNT domain and CAE domain of the ERG polypeptide and have dominant negative ERG activity. In other embodiments, the intragenic deletions results in a loss of expression of the native ERG polypeptide. Such nucleotide sequences and amino acid sequences of ERG find use in methods and compositions useful in the identification and/or the prognosis and/or predisposition and/or treatment of ALL, more particularly, the novel subtype of B-progenitor AL.02-24-2011
20120272348VIRAL VECTORS ENCODING A DNA REPAIR MATRIX AND CONTAINING A VIRION-ASSOCIATED SITE SPECIFIC MEGANUCLEASE FOR GENE TARGETING - The present invention relates to a fusion protein which comprises at least a functional meganuclease and a viral protein and in particular to fusion protein comprising at least a meganuclease, which recognises and cleaves a specific DNA target sequence and a viral peptide selected from the group Vpr and Vpx or a fragment or derivative thereof; wherein said fusion protein is able to associate with Lentivirus vector particles and following transduction into a host cell recognise and cleave said specific DNA target in vivo. The present Patent Application also relates to a viral particle comprising such a fusion protein and to the use of such fusion proteins and viral particles for gene targeting.10-25-2012
20120331574USE OF MEGANUCLEASES FOR INDUCING HOMOLOGOUS RECOMBINATION EX VIVO AND IN TOTO IN VERTEBRATE SOMATIC TISSUES AND APPLICATION THEREOF - A monomer of an I-CreI meganuclease variant wherein said monomer when in dimeric form binds and cleaves DNA.12-27-2012
20110061117MATRIX ATTACHMENT REGIONS (MARS) FOR INCREASING TRANSCRIPTION AND USES THEREOF - Isolated and purified MAR sequences of human and non-human animal origin are disclosed as are nucleotide sequences corresponding to or based on them. In particular, MARs and MAR constructs with high transcription and/or protein production enhancing activities are disclosed and so are methods for identifying such MARs, designing such MAR constructs and employing them, e.g., for high yield production of proteins.03-10-2011
20110239315MODULAR DNA-BINDING DOMAINS AND METHODS OF USE - The present invention refers to methods for selectively recognizing a base pair in a DNA sequence by a polypeptide, to modified polypeptides which specifically recognize one or more base pairs in a DNA sequence and, to DNA which is modified so that it can be specifically recognized by a polypeptide and to uses of the polypeptide and DNA in specific DNA targeting as well as to methods of modulating expression of target genes in a cell.09-29-2011
20120278909COMPOSITIONS AND METHODS FOR DETERMINING GENETIC POLYMORPHISMS IN THE TMEM216 GENE - In alternative embodiments, the invention provides nucleic acid sequences that are genetic polymorphic variations of the human TMEM216 gene, and TMEM216 polypeptide encoded by these variant alleles. In alternative embodiments, the invention provides methods of determining or predicting a predisposition to, or the presence of, a ciliopathy (or any genetic disorder of a cellular cilia or cilia anchoring structure, basal body or ciliary function) in an individual, such as a Joubert Syndrome (JS), a Joubert Syndrome Related Disorder (JSRD) or a Meckel Syndrome (MKS). In alternative embodiments, the invention provides compositions and methods for the identification of genetic polymorphic variations in the human TMEM216 gene, and methods of using the identified genetic polymorphisms and the proteins they encode, e.g., to screen for compounds that can modulate the human TMEM216 gene product, and possibly treat JS, JSRD or MKS. In alternative embodiments, the invention provides cells, cell lines and/or non-human transgenic animals that can be used as screening or model systems for studying ciliopathies and testing various therapeutic approaches in treating ciliopathies, e.g., JS, JSRD or MKS.11-01-2012
20120090042Polypeptides Having Phytase Activity And Polynucleotides Encoding Same - The present invention relates to polypeptides having phytase activity. These polypeptides have an amino acid sequence which has at least 70% identity to either of three phytases derived from the bacterium 04-12-2012
20120090041Compositions and Methods for Inhibiting Endogenous Immunoglobulin Genes and Producing Transgenic Human Idiotype Antibodies - The invention relates to transgenic animals lacking endogenous Ig and capable of producing transgenic antibodies, as well as methods of making the same. The invention further relates to methods for producing transgenic antibodies in such animals, and transgenic antibodies so produced.04-12-2012
20110277044POLYPEPTIDES HAVING ESTERASE ACTIVITY AND NUCLEIC ACIDS ENCODING THE SAME - The present invention relates to isolated polypeptides having esterase activity and isolated polynucleotides encoding the polypeptides. The invention also relates to nucleic acid constructs, vectors, and host cells comprising the polynucleotides as well as methods of producing and using the polypeptides.11-10-2011
20110277043Desaturases and Process for the Production of Polyunsaturated Fatty Acids in Transgenic Organisms - The present invention relates to polynucleotides from 11-10-2011
20100223681Assessment Method - A method of assessing the viability of a cell comprises incubating the cell in a culture medium. The culture medium includes a plurality of amino acids and the change in concentration in the medium of at least one amino acid is determined.09-02-2010
20100199365DESATURASES AND METHODS FOR PRODUCING POLYUNSATURATED FATTY ACIDS IN TRANSGENIC ORGANISMS - The present invention relates to polynucleotides from 08-05-2010
20100199364TNF SUPERFAMILY COLLECTIN FUSION PROTEINS - The present invention refers to a fusion protein comprising a TNF-superfamily (TNFSF) cytokine or a receptor binding domain thereof fused to a collectin trimerization domain, to a nucleic acid molecule encoding the fusion protein, and to a cell comprising the nucleic acid molecule. The fusion protein is present as a trimeric complex or as an oligomer thereof. The fusion protein, the nucleic acid, and the cell is suitable as pharmaceutical composition or for therapeutic, diagnostic and/or research applications.08-05-2010
20100199363ENZYMES FOR DEGRADING HERBICIDES - The present invention relates to a new type of enzyme which is able to degrade amine-containing herbicides such as glyphosate and glufosinate, as well as polynucleotides encoding these enzymes. The invention also relates to transgenic plants producing these enzymes which are resistant to an amine-containing herbicide activity. In addition, the present invention provides methods of bioremediation which rely on the activity of this new type of enzyme.08-05-2010
20130014288NOVEL REPORTER-TAGGED RECOMBINANT MEMBRANE PROTEINS WITH TRANSMEMBRANE LINKERS - Recombinant protein constructs are described that comprises a membrane protein whose N- or C-terminus in the native state is recombinantly linked through a membrane-spanning linker polypeptide to a reporter polypeptide. The reporter polypeptide may be a fluorogen activating protein capable of binding a fluorogen to detect the location and relative abundance of the membrane protein, and more specifically to detect protein trafficking to the cell surface using a cell impermeant fluorogen probe.01-10-2013
20100132059TEMPERATURE-INDUCED POLYNUCLEOTIDES AND USES THEREFOR - The present invention is based on the discovery that the transcriptional activity of both hamster mammary tumor 7 (HMT-7) and hamster layilin genes are increased when Chinese Hamster Ovary (CHO) cells are cultured at temperatures lower than 37° C. The present invention provides novel genomic, cDNA, and protein sequences of HMT-7 and a novel genomic sequence for hamster layilin. Included in the genomic sequences are novel temperature-induced promoter sequences for each; two promoter sequences are provided for HMT-7 and one promoter sequence is provided for layilin. The invention additionally provides antisense and siRNA molecules to the nucleic acid molecules of HMT-7. The invention also provides genetically engineered expression vectors comprising the novel temperature-induced promoters of the invention, which are particularly useful as part of a mammalian temperature-inducible expression system. The invention also provides host cells and/or transgenic animals comprising the novel nucleic acid molecules of the invention. The invention further provides methods of using the polynucleotides of the invention, e.g., for temperature-induced transgene expression.05-27-2010
20110162095TNFSF Single Chain Molecules - The present invention refers to single-chain fusion proteins comprising three soluble TNF superfamily (TNFSF) cytokine domains and nucleic acid molecules encoding these fusion proteins. The fusion proteins are substantially non-aggregating and suitable for therapeutic, diagnostic and/or research applications.06-30-2011
20130024958LENTIVIRAL VECTORS THAT PROVIDE IMPROVED EXPRESSION AND REDUCED VARIEGATION AFTER TRANSGENESIS - The present invention provides new lentiviral vectors that include an anti-repressor element (ARE) and, optionally, a scaffold attachment region (SAR). The lentiviral vectors provide expression of a heterologous nucleic acid in at least 50% of the cells of multiple cell types when used for lentiviral transgenesis. In certain embodiments of the invention the heterologous nucleic acid encodes an RNAi agent such as an shRNA. The invention further provides transgenic nonhuman animals generated using a lentiviral vector that includes an ARE and optional SAR. In addition, the invention provides a variety of methods for using the vectors including for achieving gene silencing in eukaryotic cells and transgenic animals, and methods of treating disease. The invention also provides animal models of human disease in which one or more genes is functionally silenced using a lentiviral vector of the invention.01-24-2013
20080250515Endoplasmic reticulum localization signals - The invention relates to cellular localization signals. In particular, the invention relates to endoplasmic reticulum localization signals in monomeric or multimeric form. The localization signals are utilized as research tools or are linked to therapeutics. Disclosed are methods of making and using polypeptides and modified polypeptides as signals to localize therapeutics, experimental compounds, peptides, proteins and/or other macromolecules to the endoplasmic reticulum of eukaryotic cells. The polypeptides of the invention optionally include linkage to reporters, epitopes and/or other experimental or therapeutic molecules. The invention also encompasses polynucleotides encoding the localization signals and vectors comprising these polynucleotides.10-09-2008
20080235816MULTIPLE INDUCIBLE GENE REGULATION SYSTEM - The present invention relates to the field of biotechnology or genetic engineering. More specifically, the present invention relates to a multiple inducible gene regulation system that functions within cells to simultaneously control the quantitative expression of multiple genes.09-25-2008
20080222742Expression Elements - The invention relates to improved genetic elements providing high levels of expression of operably-linked genes in a variety of tissues. In particular, fragments of unmethylated, CpG islands of less than 2 kb are shown to provide enhanced transgene expression and have advantages in terms of vector construction and cloning capacity.09-11-2008
20110271357COLON DISEASE TARGETS AND USES THEREOF - The present invention provides a method for diagnosing and detecting diseases associated with colon. The present invention provides one or more proteins or fragments thereof, peptides or nucleic acid molecules differentially expressed in colon diseases (CCAT) and antibodies binds to CCAT. The present invention provides that CCAT is used as targets for screening agents that modulates the CCAT activities. Further the present invention provides methods for treating diseases associated with colon.11-03-2011
20130174288ANTIBODIES FOR THE TREATMENT OF HIV - The present invention relates to isolated antibodies, or the derivatives or antigen binding fragments of same, capable of binding to CXCR4 but also of inducing conformational change of the CXCR4 homodimers and able to inhibit HIV-1 primary isolate replication in PBMC. More particularly, the present invention relates to the 515H7 and 301 aE5 monoclonal antibodies, specific to the CXCR4 protein, as well as their use for the treatment of HIV infection. Pharmaceutical compositions comprising such antibodies and a process for the selection of such antibodies are also covered.07-04-2013
20130125252NOVEL ANTI-IGF-IR ANTIBODIES AND USES THEREOF - The present invention relates to novel antibodies capable of binding specifically to the human insulin-like growth factor I receptor (IGF-IR). The invention likewise comprises the use of these antibodies as a medicament for the prophylactic and/or therapeutic treatment of cancers overexpressing IGF-IR, stimulated either by IGF1 and/or IGF2, or any pathology connected with the overexpression of said receptor as well as in processes or kits for diagnosis of illnesses connected with the overexpression of the IGF-IR and/or the IGF-I/Insulin hybrid receptor.05-16-2013
20110214193BIOMARKER FOR MICRODOMAIN DISEASE - The present invention relates to a diagnostic technique related to a biomarker for a microdomain disease and a method for detecting a microdomain disease of which manipulation is easy and which is inexpensive.09-01-2011
20080201791T Cell Line-Based Packaging Cell Line for the Production of Retroviruses by Enriching of Cd3 Expressing Cells - The present invention relates to retroviral vector systems, in particular the development of packaging or helper cell lines that are based on T cells and that are suitable for producing T cell receptor retroviruses. Thereby, the present invention relates to T cell line specific retroviral expression vectors, and mammalian T cell line-based helper cell lines. The invention further relates to methods for expressing transgenes and to T cell line specific retroviral vector systems, including biochemical kits, that utilize and/or comprise the T cell line specific retroviral expression vectors and/or mammalian T cell line-based helper cell lines.08-21-2008
20080201790Method and product for regulating cell responsiveness to external signals - The present invention relates to isolated MEKK proteins, nucleic acid molecules having sequences that encode such proteins, and antibodies raised against such proteins. The present invention also includes methods to use such proteins to regulate signal transduction in a cell. The present invention also includes therapeutic compositions comprising such proteins or nucleic acid molecules that encode such proteins and their use to treat animals having medical disorders including cancer, inflammation, neurological disorders, autoimmune diseases, allergic reactions, and hormone-related diseases. When MEKK is expressed, it phosphorylates and activates MKKs1-4 (also referred to as MEK-1, MEK-2 and JNKK1 and JNKK2).08-21-2008
20110225664MEGANUCLEASE VARIANTS CLEAVING A DNA TARGET SEQUENCE FROM A GLUTAMINE SYNTHETASE GENE AND USES THEREOF - An 1-Cre1 variant, wherein one of the two 1-Cre1 monomers has at least two substitutions, one in each of the two functional subdomains of the LAGLIDADG core domain situated respectively from positions 28 to 40 and 44 to 77 of 1-Cre1, said variant being able to cleave a DNA target sequence from the Glutamine Synthetase gene. Use of said variant and derived products for improving expression system for the production of recombinant protein.09-15-2011
20110239316ANTI-cMET ANTIBODY - Antibody capable of binding specifically to the human c-Met receptor and/or capable of specifically inhibiting the tyrosine kinase activity of said receptor, with an improved antagonistic activity, said antibody comprising a modified hinge region. A composition comprising such an antibody antagonist to c-Met and its use as a medicament for treating cancer.09-29-2011
20100313285Altering High Density Lipoprotein Levels Through UDP-N-Acetyl-Alpha-D-Galactosamine: Polypeptide N-Acetlgalactosaminyltransferase (GALNT) Modulation - Described herein are methods for detecting and treating coronary artery disease and atherosclerotic conditions based on modulating the levels of total plasma lipoprotein and HDL-C by inhibiting expression or activity of GALNT. Also described herein are methods for identifying an agent(s) useful in treating coronary artery disease or atherosclerotic conditions.12-09-2010
20090077678TRANSGENIC MOLLUSK AND METHOD FOR PRODUCING THE SAME - A transgenic mollusk which can express a desired foreign gene, and a method for producing the same are disclosed. The mollusk is a transgenic mollusk into which a desired foreign gene (excluding a gene giving resistance to a virus) is introduced, which expresses the foreign gene. This transgenic mollusk can be produced by microinjecting into gonad of male and/or female of mollusk a recombinant vector into which a desired foreign gene to be introduced or a nucleic acid containing the foreign gene is inserted; crossing the male and female to produce individuals of first generation; and selecting therefrom (an) individual(s) which express(es) the desired gene.03-19-2009
20090100535CHIMERIC DNA-BINDING PROTEINS - Chimeric proteins containing composite DNA-binding regions are disclosed together with DNA constructs encoding them, compositions containing them and applications in which they are useful.04-16-2009
20120284810ANTI-CD151 ANTIBODIES AND THEIR USE IN THE TREATMENT OF CANCER - The present invention relates to new antibodies capable of binding specifically to the human CD151 protein, especially monoclonal antibodies of murine origin, which are chimeric and humanized, and also to the amino acid and nucleic sequences coding for those antibodies. The invention also includes use of those antibodies as medicaments for the prophylactic and/or therapeutic treatment of cancers and in diagnostic methods or kits for diseases associated with overexpression of the CD151 protein. Finally, the invention includes products and/or compositions comprising such antibodies in association with antibodies and/or anti-cancer agents or conjugated with toxins and/or radioelements and their use in the prevention and/or treatment of certain cancers.11-08-2012
20110289610HCV/GBV-B CHIMERIC VIRUS - An HCV/GBV-B chimeric virus which maintains the replication function of HCV and is capable of infecting tamarin is disclosed in order to construct an HCV animal model which can be used as a development or evaluation system for therapeutic agents for HCV. The HCV/GBV-B chimeric RNA comprises an RNA of hepatitis C virus and an RNA of GB virus-B, wherein the RNA of hepatitis C virus comprises an RNA encoding leucine at the 1804th position and lysine at the 1966th position in the amino acid sequence of the polyprotein of hepatitis C virus.11-24-2011
20110314564ENZYMES AND METHODS FOR HYDROLYSING PHENYLUREAS, CARBAMATES AND ORGANOPHOSPHATES - The present invention relates to enzymes which are able to hydrolyse phenylureas, carbamates, and/or organophosphates, as well as polynucleotides encoding these enzymes. The present invention also relates to methods of hydrolysing phenylureas, carbamates, and/or organophosphates.12-22-2011
20110321183METHODS FOR LIGATION AND USES THEREOF - The present invention relates to methods for ligation. The invention provides novel reagents and methods for ligating an acyl donor compound with an acyl acceptor compound. Provided acyl donor compounds comprise a transamidase recognition sequence that allows ligation with a nucleophilic acyl acceptor in the presence of transamidase. The invention further provides kits comprising acyl donor compounds and optionally comprising other reagents for ligation.12-29-2011
20110321182SELECTION OF ANIMALS FOR DESIRED MILK AND/OR TISSUE PROFILE - The present invention is directed to mutations in the DGAT1 gene that produce an advantageous milk, tissue and/or growth rate profile in animals carrying the mutations. The present invention is also directed to methods of identifying animals carrying the mutations in order to facilitate the selection of animals with altered milk, tissue and/or growth rate traits.12-29-2011
20130191935METHOD OF REGULATING GENE EXPRESSION - The present invention relates, in general, to gene expression and, in particular, to a method of inhibiting the expression of a target gene and to constructs suitable for use in such a method.07-25-2013
20120005768Circovirus Sequences Associated With Piglet Weight Loss Disease (PWD) - The genome sequences and the nucleotide sequences coding for the PWD circovirus polypeptides, such as the circovirus structural and non-structural polypeptides, vectors including the sequences, and cells and animals transformed by the vectors are provided. Methods for detecting the nucleic acids or polypeptides, and kits for diagnosing infection by a PWD circovirus, also are provided. Method for selecting compounds capable of modulating the viral infection are further provided. Pharmaceutical, including vaccine, compositions for preventing and/or treating viral infections caused by PWD circovirus and the use of vectors for preventing and/or treating diseases also are provided.01-05-2012
20120030781LRRK2 POLYNUCLEOTIDES AND TRANSGENIC ANIMALS - A polynucleotide consisting of the base sequence of SEQ ID NO:2, or a complementary strand thereto, wherein the X is one of the group being defined by the bases A, C or T. A primer and a probe specific for that polynucleotide, wherein the primer and/or probe contains at least 10 consecutive nucleotides, and finally use of the probe for proving parkinsonism inheritance.02-02-2012
20120030780TARGETING OF SALL4 FOR THE TREATMENT AND DIAGNOSIS OF PROLIFERATIVE DISORDERS ASSOCIATED WITH MYELODYSPLASTIC SYNDROME (MDS) - The present invention discloses nucleic acids, proteins, and antibodies for SALL4 (including isoforms SALL4A, SALL4B, and SALL4C), a zinc finger transcriptional factor. Further, methods are disclosed which demonstrate that constitutive expression of SALL4 increases leukemogenic potential in cells of model animal systems. Moreover, constitutive expression of select isoforms (e.g., SALL4B) in transgenic mice demonstrate that these animals develop myelodysplastic syndrome (MDS)-like signs and symptoms, including subsequent acute myeloid leukemia (AML), which is transplantable. The disclosure also provides methods for identifying and purifying embryonic stem cells, adult stem cells, cancer stem cells, including leukemia stem cells, methods for identifying substances which bind to and/or modulate SALL4, methods for diagnosing MDS in a subject, and methods of treating a subject presenting MDS.02-02-2012
20130198877ANTISENSE OLIGONUCLEOTIDE DIRECTED REMOVAL OF PROTEOLYTIC CLEAVAGE SITES FROM PROTEINS - Described are means and methods for removing a proteolytic cleavage site from a protein, the method comprising providing a cell that expresses pre-mRNA encoding the protein with an anti-sense oligonucleotide that induces skipping of the exonic sequence that encodes the proteolytic cleavage site, and allowing translation of mRNA produced from the pre-mRNA.08-01-2013
20130205416ANTI-VIRAL AGENT - The present invention provides an agent, in particular a peptide, of formula A, comprising an amino acid sequence X1-X2-X3-X4-X5-X6 (SEQ ID NO 1) wherein X1 can be phenylalanine, isoleucine or tryptophan; X2 can be leucine or phenylalanine or alanine; X3 can be tyrosine or valine; X4 can be leucine, phenylalanine or isoleucine; 10 X5 can be phenyalanine or alanine; and X6 can be valine, arginine or tyrosine, or a fragment or variant of the peptide, wherein said peptide fragment or variant is capable of specifically binding to haemagglutinin, to inhibit the binding of a virus having haemagglutinin on its surface, for use in the treatment of a virus, for example influenza.08-08-2013
20120096571EGLN2 VARIANTS AND USE THEREOF IN PREVENTING OR TREATING THROMBOEMBOLIC DISORDERS AND CORONARY HEART DISEASES - The present invention refers to human EGLN2 variants having at position 58 of the amino acid sequence a serine or a leucine and their use in the prevention or treatment of thromboembolic or coronary heart diseases, in particular stroke, prolonged reversible ischemic neurological deficit (PRIND), transitoric ischemic attack (TIA), myocardial infarction and/or early myocardial infarction.04-19-2012

Patent applications in class Transgenic nonhuman animal (e.g., mollusks, etc.)

Patent applications in all subclasses Transgenic nonhuman animal (e.g., mollusks, etc.)